

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/00, C07K 14/00, C07H 21/00	A1	(11) International Publication Number: WO 95/23856 (43) International Publication Date: 8 September 1995 (08.09.95)
(21) International Application Number: PCT/US95/02945 (22) International Filing Date: 1 March 1995 (01.03.95) (30) Priority Data: 08/205,508 3 March 1994 (03.03.94) US (71) Applicant: ALEXION PHARMACEUTICALS, INC. [US/US]; Suite 360, 25 Science Park, New Haven, CT 06511 (US). (72) Inventors: FODOR, William, L.; 236 Wildcat Road, Madison, CT 06443 (US). ROLLINS, Scott; 12 Nutmeg Circle, Monroe, CT 06468 (US). SQUINTO, Stephen, P.; 16 Coachmans Lane, Bethany, CT 06524 (US). (74) Agent: KLEE, Maurice, M.; 1951 Burr Street, Fairfield, CT 06430 (US).	(81) Designated States: AU, BR, CA, CN, HU, JP, KR, MX, NO, NZ, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: CHIMERIC COMPLEMENT INHIBITOR PROTEINS (57) Abstract Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino terminal to the second functional domain. In this way, the chimeric protein exhibits both C3 and C5b-9 inhibitory activity. The other orientation, i.e., the orientation in which the second amino acid sequence is amino terminal to the first amino acid sequence, only produces C3 inhibitory activity. Nucleic acid molecules encoding such proteins are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

CHIMERIC COMPLEMENT INHIBITOR PROTEINSFIELD OF THE INVENTION

The present invention relates to chimeric complement inhibitor proteins (cCIPs) that contain functional domains from two complement inhibitor proteins (CIPs), the functional domain from one CIP having C3 inhibitory activity and the functional domain from the other CIP having C5b-9 inhibitory activity. More particular, the invention relates to such chimeric proteins wherein a domain having C3 inhibitory activity is amino terminal to a domain having C5b-9 inhibitory activity.

BACKGROUND OF THE INVENTIONI. The Complement System

The complement system is a complex interaction of at least 25 plasma proteins and membrane cofactors which act in a multistep, multiprotein cascade sequence in conjunction with other immunological systems of the body to defend against intrusion of foreign cells and viruses. Complement proteins represent up to about 10% of globulins in normal serum of humans and other vertebrates. Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. The resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions.

There are two main routes of complement activation: the classical pathway and the alternative pathway. These pathways share many components, and while they differ in their initial steps, they converge and share the same "terminal complement" components responsible for the activation, attack, and/or destruction of target cells.

The classical complement pathway is typically initiated by antibody recognition of and binding to an antigenic site on a target cell. The alternative pathway is usually antibody independent, and can be initiated by
5 certain molecules on pathogen surfaces. Both pathways converge at the point where complement component C3 is cleaved by an active protease (which is different in each pathway) to yield C3a and C3b. The active protease, which is referred to as C3 convertase, comprises
10 complement components C2aC4b for the classical pathway and complement components C3bBb for the alternative pathway.

C3a is an anaphylotoxin that can induce degranulation of mast cells, resulting in the release of
15 histamine and other mediators of inflammation. C3b has multiple functions. As opsonin, it binds to bacteria, viruses and other cells and particles and tags them for removal from the circulation. C3b can also form a complex with other components unique to each pathway to
20 form classical or alternative C5 convertase, which cleaves C5 into C5a (another anaphylatoxin), and C5b.

C5a, like C3a, is a potent anaphylatoxin which can cause the activation of granulocytes and platelets. Additionally, C5a is a chemoattractant for neutrophils
25 and also mediates mast cell histamine release and resulting smooth muscle contraction. C5b, on the other hand, combines with C6, C7, and C8 to form the C5b-8 complex at the surface of the target cell. Upon binding of C9 the membrane attack complex (MAC, C5b-9) is formed.
30 When sufficient numbers of MACs insert into target cell membranes, the openings they create mediate rapid lysis of the target cells. Lower, non-lytic concentrations of MACs can produce other effects. In particular, membrane insertion of small numbers of the C5b-9 complexes into
35 endothelial cells and platelets can cause potentially deleterious cell activation. In some cases activation may precede cell lysis.

Control of the complement system is necessary in order to prevent destruction of autologous cells. Since 1900 it has been known that complement-mediated cytolysis is not efficient when the complement and the target cells are from the same species. (Bordet, 1900.) Studies on the susceptibility of non-human cells to complement-mediated lysis have shown that such cells are readily lysed by human complement while they are generally resistant to lysis by complement derived from the same species. (Houle et al., 1988). This phenomenon is referred to in the art as "homologous species restriction of complement-mediated lysis." The mechanism by which such restriction takes place has been at least partially revealed by a series of experiments in which complement regulatory proteins have been identified that serve to protect cells from homologous complement-mediated damage. (Rollins et al., 1991).

II. C3 Inhibitor Proteins

A family of cell-surface proteins with shared structural features has been described each of whose actions impact on C3b.

Decay accelerating factor (DAF or CD55) exists on all cells, including red blood cells. DAF is a single chain, 70 kDa glycoprotein that is linked to the cell membrane via a glycosphosphatidylinositol (GPI) moiety which inserts into the outer leaflet of the plasma membrane bilayer.

DAF regulates complement activation at the C3 convertase stage by preventing the assembly of the C3 convertases of both the classical and alternative pathways (Medof et al., 1984; Fujita et al., 1987). Thus, DAF prevents the formation of the anaphylactic cleavage fragments C3a and C5a, in addition to inhibiting amplification of the complement cascade on host cell membranes.

DAF has been shown to act exclusively in an intrinsic manner on cells, protecting only the cell on

whose surface it resides while having no effect on neighboring cells. After extraction from human red blood cells, DAF reincorporates into cell membranes and is biologically active. Both membrane and secreted forms of DAF have been identified and their cDNAs have been cloned and characterized (Moran et al., 1992).

The nucleotide and amino acid sequences for human DAF are set forth in the Sequence Listings as SEQ ID NO:1.

Membrane cofactor protein (MCP or CD46) exists on all cells except red blood cells. MCP is a type I transmembrane glycoprotein that binds to C3b. MCP acts as a cofactor in the factor I-mediated cleavage of C3b and C4b deposited on self tissue. Therefore, the presence of bound MCP activates molecules that cleave C3b into inactive fragments, preventing the potentially cytolytic accumulation of C3b. Nucleotide and amino acid sequences for MCP can be found in Lublin, et al., 1988.

Complement receptor 1 (CR1 or CD35) is found on erythrocytes as well as a select group of leukocytes, including lymphocytes, neutrophils, and eosinophils. CR1 is a 190-280 kDa transmembrane protein that triggers the proteolytic degradation of membrane bound C3b molecules with which it comes in contact. It also promotes the clearance of immune complexes. Nucleotide and amino acid sequences for CR1 can be found in Wong, et al., 1985.

Factor H and C4b-binding protein each inhibit the activity of alternative pathway C3 convertase. Nucleotide and amino acid sequences for factor H can be found in Ripoché, et al., 1988; nucleotide and amino acid sequences for C4b-binding protein can be found in Chung, et al., 1985.

The genes encoding all of these C3 inhibitory proteins have been mapped to the long arm of chromosome 1, band 1q32, and constitute a locus designated the RCA (Regulators of Complement Activity) gene cluster. Notable in the molecular structure of these C3 inhibitory

proteins is a common structural motif of approximately 60 amino acids designated the SCR (short consensus repeat), which is normally present in multiple copies that are not necessarily identical. See Perkins et al. 1988; Coyne, et al., 1992.

5 The SCR motif of these C3 inhibitory proteins has four conserved cysteine residues and conserved tryptophan, glycine, and phenylalanine/tyrosine residues. The SCRs are usually followed by a long serine/threonine rich region.

10 In DAF and MCP, the SCRs are known to encode functional domains necessary for full complement inhibitory activity (Adams, et al., 1991). DAF is composed of 4 SCRs juxtaposed to a serine/threonine rich region on the carboxyl terminal side of the SCRs. Most, if not all, of the functional domains are reported to reside in SCRs 2 through 4 (Coyne et al., 1992). In SEQ ID NO:1, the 4 SCRs of DAF comprise amino acid 1 through amino acid 61 (SCR 1), amino acid 62 through amino acid 125 (SCR 2), amino acid 126 through amino acid 187 (SCR 3), and amino acid 188 through amino acid 250 (SCR 4), Lublin, et al., 1989.

15 The phrase "C3 inhibitory activity" is used herein to describe the effects of C3 inhibitor molecules of the foregoing types on the complement system and thus includes activities that lead to disruption of the C3 convertase complex and/or activities that are responsible for the degradation of C3b.

25 III. C5b-9 Inhibitor Proteins

30 The archetypical C5b-9 inhibitor protein is the human glycoprotein known as CD59. The nucleotide and amino acid sequences for human CD59 are set forth in the Sequence Listings as SEQ ID NO:2.

35 CD59 is found associated with the membranes of cells including human erythrocytes, lymphocytes, and vascular endothelial cells. It serves to prevent assembly of functional MACs and thus protects cells from

complement-mediated activation and/or lysis. CD59 has an apparent molecular mass of 18-21 kilodaltons (kD) and, like DAF, is tethered to the outside of the cell membrane by a GPI anchor. See, for example, Sims et al., U.S. Patent No. 5,135,916.

CD59 appears to function by competing with C9 for binding to C8 in the C5b-8 complex, thereby decreasing the formation of the C5b-9 membrane attack complex. (Rollins et al., 1990.) CD59 thus acts to reduce both cell activation and cell lysis by terminal complement MACs. This activity of CD59 is for the most part species-restricted, most efficiently blocking the formation of MACs under conditions where C8 and C9 are derived from homologous (i.e., human) serum. (Venneker et al., 1992.)

The assimilation of purified CD59 into the plasma membrane of non-human erythrocytes (which appear to be protected from homologous complement lysis by the action of their own cell surface complement inhibitor proteins) and oligodendrocytes (brain cells which are believed to be protected less, if at all, by cell surface proteins, but may be protected in vivo by the blood brain barrier) has shown that CD59 can protect these cells from lysis mediated by human complement. (Rollins, et al., 1990; Rollins, et al., 1991; Stefanova, et al., 1989; Meri, et al., 1990; Whitlow, et al., 1990; Okada, et al., 1989; and Wing, et al., 1992).

cDNAs encoding CD59 have been cloned and the structure of the CD59 gene has been characterized (Davies, et al., 1989; Okada, et al., 1989; Philbrick, et al., 1990; Sawada, et al., 1990; and Tone, et al., 1992). Non-human mammalian cells transfected with the cloned CD59 cDNA, and thereby expressing the human CD59 protein on their cell surfaces, have been shown to gain resistance to complement-mediated cell lysis (Zhao, et al., 1991; and Walsh, et al., 1991).

CD59 has been reported to be structurally related to the murine Ly-6 antigens (Philbrick, et al., 1990; and Petranks, et al., 1992). The genes encoding these antigens, also known as T-cell activating proteins, are members of the Ly-6 multigene family, and include Ly-6A.2, Ly-6B.2, Ly-6C.1, Ly-6C.2, and Ly-6E.1. The gene encoding the murine thymocyte B cell antigen ThB is also a member of this family (Shevach, et al. 1989; and Gumley, et al., 1992).

A distinguishing feature of the amino acid sequences of the proteins of the Ly-6 family is the arrangement of their cysteine residues. Cysteine residues of many proteins form a structural element referred to in the art as a "cysteine backbone." In those proteins in which they occur, cysteine backbones play essential roles in determining the three dimensional folding, tertiary structure, and ultimate function of the protein molecule.


The proteins of the Ly-6 multigene family, as well as several other proteins share a particular cysteine backbone structure referred to herein as the "Ly-6 motif". For example, the human urokinase plasminogen activator receptor (uPAR; Roldan, et al., 1990) and one of several squid glycoproteins of unknown function (Sgp2; Williams, et al., 1988) contain the Ly-6 motif.

Subsets of proteins having the Ly-6 motif can be identified by the presence of conserved amino acid residues immediately adjacent to the cysteine residues. Such conservation of specific amino acids within a subset of proteins can be associated with specific aspects of the folding, tertiary structure, and ultimate function of the proteins. These conserved patterns are most readily perceived by aligning the sequences of the proteins so that the cysteine residues are in register.


As discussed fully in copending, commonly assigned, U.S. patent application Serial No. 08/105,735, filed August 11, 1993, by William L. Fodor, Scott Rollins, Russell Rother, and Stephen P. Squinto, and entitled

"Complement Inhibitor Proteins of Non-human Primates", the relevant portions of which are incorporated herein by reference, and in Rother, et al., 1994, a series of non-human primate C5b-9 inhibitory proteins have been identified which are characterized by a cysteine backbone structure which defines a specific subset of the general Ly-6 motif.

Specifically, these non-human primate CIPs include polypeptides comprising a cysteine backbone with a Ly-6 motif characterized by the formula:



In addition, the non-human primate C5b-9 inhibitory proteins include amino acid sequences conforming to the following formula:



In both formulas, the X in X_n indicates a peptide containing any combination of amino acids, the n in X_n represents the length in amino acid residues of the peptide, and each X at any position can be the same as or different from any other X of the same length in any other position.

As discussed fully in commonly assigned, copending PCT application Serial No. PCT/US 93/00672, filed January 12, 1993, by Bernhard Fleckenstein and Jens-Christian Albrecht, and entitled "Complement Regulatory Proteins of Herpesvirus Saimiri", the relevant portions of which are incorporated herein by reference, and in Albrecht, et al., 1992, a protein of the herpesvirus saimiri having C5b-9 inhibitory activity has been discovered (referred to herein as "HVS-15"). This viral protein has the Ly-6 motif which is characteristic of the non-human primate C5b-9 inhibitory proteins discussed above, i.e., its structure is described by formulas (1) and (2) above.

The phrase "C5b-9 inhibitory activity" is used herein to describe the effects of C5b-9 inhibitor molecules of the foregoing types on the complement system and thus includes activities that lead to inhibition of the cell activating and/or lytic function of the membrane attack complex (MAC).

V. Complement Associated Pathologies

Human studies and studies using animal models of human disorders have implicated CIPs in the pathologies associated with a number of disorders, including the following.

Transplantation: Intrinsic activation of complement attack via the alternative pathway during storage of donor organs is responsible for certain problems associated with organ transplantation which arise as a result of endothelial cell stimulation and/or lysis by the C5b-9 MAC (Brasile, et al. 1985). Ex vivo complement attack leads to reduced vascular viability and reduced vascular integrity when stored organs are transplanted, increasing the likelihood of transplant rejection.

Ten percent of allogeneic transplanted kidneys with HLA-identical matches are rejected by in vivo immunologic mechanisms (Brasile, et al. 1987). In 78% of the patients who reject organs under these conditions, cytotoxic antibodies binding to molecules on the surfaces of vascular endothelial cells are seen (Brasile, et al., 1987). Such antibody cytotoxicity is mediated by complement attack, and is responsible for the rejection of transplanted solid organs including kidneys and hearts (Brasile, et al., 1987; Brasile et al., 1985). Antibody primed, complement-mediated rejection is usually rapid and irreversible, a phenomenon referred to as hyperacute rejection.

In the xenogeneic setting, as when non-human organs are transplanted into human patients, activation of complement attack by antibodies directed against molecules on the surfaces of endothelial cells lining the

vessels of the donor organ is almost always observed. The prevalence of such xenoreactive antibodies accounts for the nearly universal occurrence of hyperacute rejection of xenografts (Dalmasso, et al., 1992). Old world primates, including humans, have high levels of preexisting circulating "natural" antibodies that predominantly recognize carbohydrate determinants expressed on the surface of xenogeneic cells from discordant species. Recent evidence indicates that most of these antibodies react with galactose in an α 1-3 linkage with galactose (Gal(α 1-3)Gal) (Sandrin, et al., 1993).

Old world primates lack the appropriate functional α -1,3-galactose transferase and thus do not express this carbohydrate epitope. Therefore, following transplantation of a vascularized xenogeneic donor organ, these high-titer antibodies bind to the Gal(α 1-3)Gal epitope on the vascular endothelium and activate the recipient's complement through the classical pathway. The massive inflammatory response that ensues from activation of the complement cascade leads to the destruction of the donor organ within minutes to hours.

Xenoreactive antibodies are not exclusively responsible for hyperacute rejection of discordant organs in all cases. For example, erythrocytes from some species can activate human complement via the alternative pathway and newborn piglets raised to be free of preformed antibodies reject xenografts almost immediately. It is therefore likely that in some species combinations, activation of the alternative complement pathway contributes to graft rejection.

Endogenously-expressed, membrane-associated complement inhibitory proteins normally protect endothelial cells from autologous complement. However, the species restriction of complement inhibitors makes them relatively ineffective with respect to regulating discordant xenogeneic serum complement. The lack of

effective therapies aimed at eliminating this antibody and complement-mediated hyperacute rejection presents a major barrier to the successful transplantation of discordant animal organs into human recipients.

5 Recently, a report on a baboon-to-human liver transplant has been published in which the xenogeneic donor organ failed to exhibit signs of hyperacute rejection (Starzl, et al., 1993). The low levels of
10 anti-baboon antibodies likely to be present in human blood make hyperacute responses less likely. However, it is believed that recently discovered baboon CIPs, which have been shown to be related to CD59 and to be effective against human complement, also played a role in maintaining the integrity of this xenotransplanted organ.
15 (See U.S. patent application Serial No. 08/105,735, referred to above.)

 The lack of hyperacute rejection seen in the baboon to human xenotransplant discussed above suggests that complement inhibitor proteins effective against human
20 complement may, in combination with other anti-rejection strategies, allow safe and effective xenotransplantation of transgenic animal organs expressing such proteins into human patients.

Paroxysmal Nocturnal Hemoglobinuria: A complement
25 mediated disease that involves the alternative pathway of complement activation is the stem cell disorder paroxysmal nocturnal hemoglobinuria. Complement inhibitory proteins, including CD59, are absent from the membranes of the most hemolytically sensitive
30 erythrocytes found in patients with this disease. The lack of these proteins is thought to potentiate the complement-mediated lysis of red blood cells that characterizes the disease (see Venneker et al., 1992). The use of chimeric terminal complement inhibitor
35 proteins in the treatment of PNH cells is discussed in copending, commonly assigned, U.S. patent application Serial No. 08/206,189, entitled "Method for the Treatment

of Paroxysmal Nocturnal Hemoglobinuria," which is being filed concurrently herewith in the names of Russell Rother, Scott Rollins, Seth A. Fidel, and Stephen P. Squinto.

5 VI. CIPs with Modified Membrane Anchors

Work has been performed in which CIPs with modified membrane anchors have been generated in order to study the functional consequences of altering the means of attachment of GPI-anchored proteins to the outer cell
10 surface. In these studies, the native cell surface anchoring of the CIPs has been varied from their natural GPI anchors by substitution of other anchoring moieties (Su, et al., 1991; and Lublin, et al., 1991).

For example, derivatives of DAF, containing amino
15 acids 1-304 of DAF fused to the transmembrane domain of MCP (i.e., amino acids 270-350 of MCP) or to the transmembrane domain of the human major histocompatibility protein HLA-B44 (i.e., amino acids 262-338 of HLA-B44) have been reported to retain levels
20 of function equivalent to native DAF (Lublin, et al., 1991).

Derivatives of CD59, containing amino acids 1-77 of CD59 fused to the transmembrane domain of MCP (i.e., amino acids 270-350 of MCP) have been shown to retain
25 levels of function equivalent to native CD59 in copending, commonly assigned, U.S. patent application Serial No. 08/205,720, entitled "Terminal Complement Inhibitor Fusion Genes and Proteins," which is being filed concurrently herewith in the names of Russell
30 Rother, Scott Rollins, and Stephen P. Squinto.

SUMMARY OF THE INVENTION

In view of the foregoing, it is an object of the present invention to provide novel chimeric proteins for use in inhibiting the complement system. To achieve this
35 and other objects, the invention provides cCIPs that contain functional domains of two CIPs, one of the functional domains having C3 inhibitory activity and the

other functional domain having C5b-9 inhibitory activity, where the C3 inhibitory activity is amino terminal to the C5b-9 inhibitory activity. In the preferred forms of the invention, the C3 and C5b-9 inhibitory activities are
5 directed against the human complement system.

The invention also provides 1) nucleic acid molecules encoding such cCIPs, 2) transgenic cells, tissues, organs, and animals containing such nucleic acid molecules, 3) expression vectors containing the nucleic
10 acid molecules, and 4) host cells containing the expression vectors.

Significantly, as a result of their structure, i.e., the ordering of the inhibitory activities within the chimeric molecule, the cCIPs of the invention
15 simultaneously exhibit both C3 inhibitory activity and C5b-9 inhibitory activity, a result not previously achieved in the art.

In accordance with the invention, these chimeric proteins and the polynucleotides encoding them may be
20 used as components of therapeutic agents for the prevention and/or treatment of complement-mediated pathologies. The protection from complement attack offered by the cCIPs of the invention can be provided via gene transfer for the therapeutic prevention of
25 pathologic complement attack in, for example, transplantation. In a preferred form of such therapy, the expression of the cCIP can be directed to the surfaces of cells of non-human animal organs in order to protect such organs from complement attack upon
30 transplantation into a human patient.

The invention is particularly advantageous in the production of transgenic animals. Microinjection of recombinant DNA into the pronuclei of animal ova has become a routine procedure for generating transgenic
35 animals. However, since this technology is dependent on random integration of DNA, it is difficult to achieve targeted cellular expression of two distinct heterologous

proteins by the simultaneous microinjection of their respective DNAs, as would be required if C3 inhibitory activity and C5b-9 inhibitory activity were to be achieved through the use of individual CIPs. The present invention overcomes this technological hurdle since it provides a novel single gene which encodes both C3 and C5b-9 inhibitory activity in a single protein.

Further, since many CIPs, in particular, DAF and CD59, are anchored to the plasma membrane via glycopospholipid moieties (GPI anchors), it is additionally difficult to express high levels of multiple GPI-anchored CIPs on a single cell in that the biochemical and enzymatic machinery required to form a GPI anchor is limited. This is a further advantage of the invention in cases where the functionality of GPI-anchored CIPs is desired.

In summary, the cCIPs of the present invention provide the advantages that: (1) they act simultaneously as both a C3 and a C5b-9 inhibitor; (2) they require only a single random integration event for expression in transgenic animals thereby significantly increasing the opportunity for the high level expression of two complement inhibitors on a given cell type of the transgenic animal (e.g., endothelial cells); and (3) the expression of a single bifunctional GPI-anchored cCIP is not a burden on the cellular machinery needed to synthesize GPI anchors in those cases where the cCIP is attached to the cell membrane by a GPI anchor.

In connection with this last advantage, higher levels of complement inhibitor activity can be achieved than would be achieved by trying to express two independent GPI-anchored recombinant CIPs in a single cell. This property is a particularly significant advantage in that the degree of complement protection offered to a xenogeneic cell is directly proportional to the number of molecules of complement inhibitor expressed on a cell's surface. See Zhao et al., 1991.

In certain preferred embodiments of the invention, the functional domain having C3 inhibitory activity is DAF or derived from DAF and the functional domain having C5b-9 inhibitory activity is human CD59 or derived from human CD59.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a schematic diagram of the molecular structure of a cCIP (DAF/SCR 2-4-CD59) constructed in accordance with the invention and identified as the "DC" construct (chimera DC). This cCIP has its C3 inhibitory activity amino terminal to its C5b-9 inhibitory activity. Figure 1B is a schematic diagram of the molecular structure of a chimeric molecule (CD59-DAF SCR 1-4) having the opposite orientation and designated "CD" (chimera CD). The DC molecule exhibits both C3 and C5b-9 inhibitory activity; the CD molecule exhibits only C3 inhibitory activity.

Figure 2 shows the results of flow cytometric analysis of the cell surface expression of the DC and CD molecules. In Figures 2A and 2B, MEM43 anti-CD59 mAb was used, while in Figures 2C and 2D, BRIC216 anti-DAF mAb was used.

Figure 3 shows the results of flow cytometric analysis of the cell surface expression of the DC cCIP before and after treatment with PI-PLC. The clone used to prepare these figures was DC-A5. In Figure 3A, MEM43 anti-CD59 mAb was used, while in Figure 3B, BRIC216 anti-DAF mAb was used.

Figure 4 shows the results of flow cytometric analysis of the degree of C3 deposition on the surface of mammalian cells expressing the DC cCIP following incubation with increasing concentrations of whole human serum (5% in Figure 4A; 10% in Figure 4B; 20% in Figure 4C; and 40% in Figure 4D). Cell surface C3 deposition (usually in the form of proteolytic fragments of C3) is a measure of C3 convertase activity. In this figure, the

degree of C3 convertase inhibition provided by DC is compared with that provided by CD, DAF, and CD59.

Figure 5 illustrates the protection of mammalian cells from complement lysis by CD59, DAF, CD, and DC.

5 The foregoing drawings, which are incorporated in and constitute part of the specification, illustrate certain aspects of the preferred embodiments of the invention and, together with the description, serve to

explain certain principles of the invention. It is to be understood, of course, that both the drawings and the description are explanatory only and are not restrictive of the invention.

5 DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. The cCIPs of the Invention

 As discussed above, the present invention relates to cCIPs which comprise an amino acid sequence having C3 inhibitory activity (hereinafter referred to as a "C3/CIP sequence") and an amino acid sequence having C5b-9 inhibitory activity (hereinafter referred to as a "C5b-9/CIP sequence"), wherein the C3/CIP sequence is amino terminal to the C5b-9/CIP sequence.

 The C3/CIP sequence provides the cCIP with C3 inhibitory activity and the C5b-9/CIP sequence provides it with C5b-9 inhibitory activity. The amino acid sequence having C3 inhibitory activity can comprise the entire amino acid sequence for a naturally occurring CIP or a portion thereof, such as one or more SCRs of the CIP.

 For example, the C3/CIP sequence can be the mature DAF molecule (i.e., amino acids 1 through 347 of SEQ ID NO:1) or the mature MCP molecule (i.e., amino acids 1 through 350 of SEQ ID NO:3).

 Alternatively, the C3/CIP sequence can be a portion of a naturally occurring C3 inhibitor protein. Following the procedures used to identify functional domains of DAF and MCP (Adams, et al., 1991), functional domains of other C3 inhibitors can be identified and used in accordance with the present invention. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent molecule.

 Particularly useful portions of mature C3 inhibitor proteins for use in the present invention comprise one or more of the mature molecule's SCRs. As discussed above, these SCRs are normally approximately 60 amino acids in

length and have four conserved cysteine residues which form disulfide bonds, as well as conserved tryptophan, glycine, and phenylalanine/tyrosine residues. In general, more than one SCR is used in the practice of the invention.

As illustrated by the examples presented below, a particularly preferred C3/CIP sequence comprises SCRs 2 through 4 of DAF.

The C5b-9/CIP sequence can comprise the entire amino acid sequence for a naturally occurring C5b-9 inhibitor protein or a portion thereof. For example, the C5b-9/CIP sequence can be the mature CD59 molecule (i.e., amino acids 1 through 103 of SEQ ID NO:2), or a non-human primate C5b-9 inhibitor protein (e.g., amino acids 1 through 103 of SEQ ID NO:4, amino acids 1 through 101 of SEQ ID NO:5, amino acids 1 through 106 of SEQ ID NO:6, amino acids 1 through 103 of SEQ ID NO:7, or amino acids 1 through 103 of SEQ ID NO:8), or a mature HVS-15 inhibitor protein (i.e., amino acids 1 through 102 of SEQ ID NO:9).

Alternatively, the C5b-9/CIP sequence can be a portion of a naturally occurring C5b-9 inhibitor protein. Active portions suitable for use in the present invention can be identified using a variety of assays for C5b-9 inhibitory activity known in the art. See Rollins, et al., 1990; Rollins, et al., 1991; Zhao, et al., 1991; and Rother, et al., 1994. For example, as demonstrated in copending application Serial No. 08/205,720, entitled "Terminal Complement Inhibitor Fusion Genes and Proteins," which is referred to above, the relevant portions of which are incorporated herein by reference, amino acids 1 through 77 of CD59 comprise a portion of the CD59 molecule having C5b-9 inhibitory activity. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent molecule.

As discussed above, naturally occurring C5b-9 inhibitor proteins generally share a common motif which can be described by formulas (1) or (2) above. Preferred portions of mature C5b-9 inhibitor proteins for use with the present invention are those having the amino acid sequence defined by these formulas. Petranka et al., 1993, and Norris et al., 1993, have reported that in CD59 (SEQ ID NO:2), the disulfide bond between Cys6 and Cys13, as well as the disulfide bond between Cys64 and Cys69, can be disrupted by replacement of these cysteines with serines without substantially compromising the functionality of CD59. These cysteines correspond to the second, third, ninth, and tenth cysteines in the above formulas. Accordingly, portions of mature C5b-9 inhibitor proteins having the above formulas but with all or some of the above cysteines replaced with serine, or another amino acid, can be used in the practice of the invention.

As discussed above, the critical aspect of the invention is the order in which the amino acid sequence having C3 inhibitory activity and the amino acid sequence having C5b-9 inhibitory activity appear in the chimeric molecule. As demonstrated by the examples presented below, the amino acid sequence having C3 inhibitory activity must be amino terminal to the amino acid sequence having C5b-9 inhibitory activity. The opposite order only produces C3 inhibitory activity.

The amino acid sequence having C3 inhibitory activity and the amino acid sequence having C5b-9 inhibitory activity do not have to be directly attached to one another. Rather, a linker sequence can separate these two sequences. The linker preferably comprises between one and about ten amino acids, although more amino acids can be used if desired. In the examples presented below, glycines were used to form the linker. This amino acid has been found to perform successfully in other chimeric proteins which include linker regions.

See Curtis, et al., "Fusion Proteins Comprising GM-CSF and IL-3" U.S. Patent No. 5,073,627. Other amino acids, as well as combinations of amino acids, can be used in the linker region if desired.

5 In the examples presented below, the amino acid sequence having C5b-9 inhibitory activity includes a GPI-anchor which attaches the chimeric CIP to the cell membrane. CIPs having C5b-9 inhibitory activity and attached to the cell membrane by a transmembrane domain,
10 rather than a GPI-anchor, are described in copending application Serial No. 08/205,720, entitled "Terminal Complement Inhibitor Fusion Genes and Proteins," which is referred to above, the relevant portions of which are incorporated herein by reference. Such transmembrane
15 domains for cell membrane attachment can be used in the practice of the present invention.

As discussed above, the cCIPs of the invention through the ordering of the C3/CIP sequence and the C5b-9/CIP sequence exhibit both C3 inhibitory activity and
20 C5b-9 inhibitory activity. The chimeric molecules exhibit at least about 25% and preferably at least about 50% of the inhibitory activity of the parent inhibitor protein from which the chimera is constructed. In this way, the advantages of providing both types of complement
25 inhibition in one molecule, as discussed above, are achieved.

II. cCIP Genes and Vectors Containing Such Genes

Molecules comprising nucleotide sequences encoding the cCIPs of the invention can be prepared using a
30 variety of techniques now known or subsequently developed in the art. For example, the cCIPs can be produced using PCR generation and/or restriction digestion of cloned genes to generate fragments encoding amino acid sequences having C3 and C5b-9 inhibitory activities. These
35 fragments can be assembled using PCR fusion or enzymatic ligation of the restriction digestion products (Sambrook, et al., 1989; Ausubel et al., 1992). Alternatively, the

nucleic acid molecules encoding the cCIPs of the invention or any or all of the nucleic acid fragments used to assemble the chimeric genes for the cCIPs can be synthesized by chemical means (Talib, et al., 1991).

5 The nucleic acid molecules which encode the cCIPs of the invention can contain additional sequences to those which encode the amino acid sequences which impart C3 and C5b-9 inhibitory activity to the molecule. For example, as discussed above, the chimeric protein can include a
10 linker sequence, in which case the nucleic acid molecule will contain a corresponding sequence which codes for the linker. In addition, to allow for processing by host cells, the nucleic acid sequence will preferably encode a signal peptide at its 5' end which directs the
15 transport of the chimeric protein to the exterior of the cell. A suitable leader sequence is one naturally associated with a CIP, such as, the leader sequence for CD59, i.e., amino acids -25 through -1 of SEQ ID NO:2.

 In cases where only a portion of a full length CIP
20 having the desired inhibitory activity is included in the chimeric molecule, the cloning procedure can begin with the nucleic acid sequence for the full CIP molecule. The desired portion of the nucleic acid molecule can then be obtained from the full molecule using PCR or restriction
25 digestion techniques.

 In addition to the foregoing, the present invention provides recombinant expression vectors which include nucleic acid fragments encoding the cCIPs of the invention. The nucleic acid molecule coding for such a
30 chimeric protein can be inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein-encoding sequence. The necessary transcriptional and translational signals can also be
35 supplied by the genes used to construct the fusion genes of the invention and/or their flanking regions.

The transcriptional and translational control sequences for expression vector systems to be used to direct expression in vertebrate cells may be provided by viral sources. For example, commonly used promoters and enhancers are derived from Polyoma virus, Adenovirus, Simian Virus 40 (SV40), the Molony murine leukemia virus (MMLV), including the long terminal repeat (MMLV-LTR), and human cytomegalovirus (CMV), including the cytomegalovirus immediate-early gene 1 promoter and enhancer. Retroviral expression vectors are a preferred system for expression of the cCIPs of the invention.

The manipulation of retroviral nucleic acids to construct retroviral vectors and packaging cells is accomplished using techniques known in the art. See Ausubel, et al., 1992, Volume 1, Section III (units 9.10.1 - 9.14.3); Sambrook, et al., 1989; Miller, et al., 1989; Eglitis, et al., 1988; U.S. Patents Nos. 4,650,764, 4,861,719, 4,980,289, 5,122,767, and 5,124,263; as well as PCT Patent Publications Nos. WO 85/05629, WO 89/07150, WO 90/02797, WO 90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO 92/14829, and WO 93/14188.

In particular, the retroviral vectors of the invention can be prepared and used as follows. First, a cCIP retroviral vector is constructed and packaged into non-infectious transducing viral particles (virions) using an amphotropic packaging system, preferably one suitable for use in gene therapy applications.

Examples of such packaging systems are found in, for example, Miller, et al., 1986; Markowitz, et al., 1988; Cosset, et al., 1990; U.S. Patents Nos. 4,650,764, 4,861,719, 4,980,289, 5,122,767, and 5,124,263, and PCT Patent Publications Nos. WO 85/05629, WO 89/07150, WO 90/02797, WO 90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO 92/14829, and WO 93/14188. A preferred packaging cell is the PA317 packaging cell line (ATCC CRL 9078).

The generation of "producer cells" is accomplished by introducing retroviral vectors into the packaging cells. Examples of such retroviral vectors are found in, for example, Korman, et al., 1987; Morgenstern, et al., 1990; U.S. Patents Nos. 4,405,712, 4,980,289, and 5,112,767; and PCT Patent Publications Nos. WO 85/05629, WO 90/02797, and WO 92/07943. A preferred retroviral vector is the MMLV derived expression vector pLXSN (Miller, et al., 1989). The retroviral vector used in the practice of the present invention will be modified to include the chimeric gene encoding the cCIP.

The producer cells generated by the foregoing procedures are used to produce the retroviral vector particles (virions). This is accomplished by culturing of the cells in a suitable growth medium. Preferably, the virions are harvested from the culture and administered to the target cells which are to be transduced, e.g., xenogeneic cells to be used for transplantation into a patient whose complement can be inhibited by the cCIP, cells of a xenogeneic organ to be used for transplantation into such a patient, the patient's own cells, and other cells to be protected from complement attack, as well as stem cells such as embryonic stem cells, which can be used to generate transgenic cells, tissues, or organs for transplantation. Alternatively, when practicable, the target cells can be co-cultured with the producer cells. Suitable buffers and conditions for stable storage and subsequent use of the virions can be found in, for example, Ausubel, et al., 1992.

Pharmaceutical compositions containing the retroviral vector particles of the invention can be administered in a variety of unit dosage forms. The dose will vary according to, e.g., the particular vector, the manner of administration, the particular disease being treated and its severity, the overall health and condition and age of the patient, the condition of the

cells being treated, and the judgment of the physician. Dosage levels for transduction of mammalian cells are generally between about 10^6 and 10^{14} colony forming units of retroviral vector particles per treatment.

5 A variety of pharmaceutical formulations can be used for administration of the retroviral vector particles of the invention. Suitable formulations are found in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985, and
10 will include a pharmaceutically effective carrier, such as saline, buffered (e.g., phosphate buffered) saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions, and the like. The formulations may contain pharmaceutically acceptable auxiliary substances
15 as required, such as, tonicity adjusting agents, wetting agents, bactericidal agents, preservatives, stabilizers, and the like.

III. Transgenic Animals

 In accordance with certain aspects of the invention,
20 the nucleic acid molecules of the present invention are used to generate engineered transgenic animals (for example, rodent, e.g., mouse, rat, capybara, and the like, lagomorph, e.g., rabbit, hare, and the like, ungulate, e.g., pig, cow, goat, sheep, and the like,
25 etc.) that express the cCIPs of the invention on the surfaces of their cells (e.g., endothelial cells) using techniques known in the art. These techniques include, but are not limited to, microinjection, e.g., of pronuclei, electroporation of ova or zygotes, nuclear
30 transplantation, and/or the stable transfection or transduction of embryonic stem cells derived from the animal of choice.

 A common element of these techniques involves the preparation of a transgene transcription unit. Such a
35 unit comprises a DNA molecule which generally includes: 1) a promoter, 2) the nucleic acid sequence of interest, i.e., the sequence encoding the cCIP of the present

invention, and 3) a polyadenylation signal sequence. Other sequences, such as, enhancer and intron sequences, can be included if desired. The unit can be conveniently prepared by isolating a restriction fragment of a plasmid vector which expresses the cCIP protein in, for example, mammalian cells. Preferably, the restriction fragment is free of sequences which direct replication in bacterial host cells since such sequences are known to have deleterious effects on embryo viability.

10 The most well known method for making transgenic animals is that used to produce transgenic mice by superovulation of a donor female, surgical removal of the egg, injection of the transgene transcription unit into the pro-nuclei of the embryo, and introduction of the transgenic embryo into the reproductive tract of a pseudopregnant host mother, usually of the same species. See Wagner, U.S. Patent No. 4,873,191, Brinster, et al., 1985, Hogan, et al., 1986, Robertson 1987, Pedersen, et al., 1990.

20 The use of this method to make transgenic livestock is also widely practiced by those of skill in the art. As an example, transgenic swine are routinely produced by the microinjection of a transgene transcription unit into pig embryos. See, for example, PCT Publication No. WO92/11757 In brief, this procedure may, for example, be performed as follows.

30 First, the transgene transcription unit is gel isolated and extensively purified through, for example, an ELUTIP column (Schleicher & Schuell, Keene, NH), dialyzed against pyrogen free injection buffer (10mM Tris, pH7.4 + 0.1mM EDTA in pyrogen free water) and used for embryo injection.

35 Embryos are recovered from the oviduct of a hormonally synchronized, ovulation induced sow, preferably at the pronuclear stage. They are placed into a 1.5 ml microfuge tube containing approximately 0.5 ml of embryo transfer media (phosphate buffered saline with

10% fetal calf serum). These are centrifuged for 12 minutes at 16,000 x g in a microcentrifuge. Embryos are removed from the microfuge tube with a drawn and polished Pasteur pipette and placed into a 35 mm petri dish for examination. If the cytoplasm is still opaque with lipid such that the pronuclei are not clearly visible, the embryos are centrifuged again for an additional 15 minutes. Embryos to be microinjected are placed into a drop of media (approximately 100 μ l) in the center of the lid of a 100 mm petri dish. Silicone oil is used to cover this drop and to fill the lid to prevent the medium from evaporating. The petri dish lid containing the embryos is set onto an inverted microscope equipped with both a heated stage (37.5-38°C) and Hoffman modulation contrast optics (200X final magnification). A finely drawn and polished micropipette is used to stabilize the embryos while about 1-2 picoliters of injection buffer containing approximately 200-500 copies of the purified transgene transcription unit is delivered into the nucleus, preferably the male pronucleus, with another finely drawn and polished micropipette. Embryos surviving the microinjection process as judged by morphological observation are loaded into a polypropylene tube (2 mm ID) for transfer into the recipient pseudopregnant sow.

Offspring are tested for the presence of the transgene by isolating genomic DNA from tissue removed from the tail of each piglet and subjecting about 5 micrograms of this genomic DNA to nucleic acid hybridization analysis with a transgene specific probe.

Another commonly used technique for generating transgenic animals involves the genetic manipulation of embryonic stem cells (ES cells) as described in PCT Patent Publication No. WO 93/02188 and Robertson, 1987.

In accordance with this technique, ES cells are grown as described in, for example, Robertson, 1987, and in U.S. Patent No. 5,166,065 to Williams et al. Genetic material

is introduced into the embryonic stem cells by, for example, electroporation according, for example, to the method of McMahon, et al., 1990, or by transduction with a retroviral vector according, for example, to the method of Robertson, et al., 1986, or by any of the various techniques described by Lovell-Badge, 1987.

Chimeric animals are generated as described, for example, in Bradley, 1987. Briefly, genetically modified ES cells are introduced into blastocysts and the modified blastocysts are then implanted in pseudo-pregnant female animals. Chimeras are selected from the offspring, for example by the observation of mosaic coat coloration resulting from differences in the strain used to prepare the ES cells and the strain used to prepare the blastocysts, and are bred to produce non-chimeric transgenic animals.

Other methods for the production of transgenic animals are disclosed in U.S. Patent No. 5,032,407 to Wagner et al., and PCT Publication No. WO90/08832.

Among other applications, transgenic animals prepared in accordance with the invention are useful as model systems for testing the xenotransplantation of their engineered tissues or organs and as sources of engineered tissues or organs for xenotransplantation. The expression of functional cCIPs on the surfaces of endothelial cells and/or other cell types in the tissues and organs (e.g., hormone producing cells such as those in the pancreatic islets) of the transgenic animals will provide enhanced protection to those cells, tissues and organs from hyperacute complement-mediated rejection following xenotransplantation in recipient animals, e.g., humans, whose complement can be inhibited by the cCIP. In addition to their use in producing organs for transplantation, the cCIP nucleic acid constructs of the invention can also be used to engineer cultured cells (e.g., endothelial cells) of various species for subsequent use in transplantation.

IV. Representative Modifications

Although specific embodiments of the invention are described and illustrated herein, it is to be understood that modifications can be made without departing from the invention's spirit and scope.

For example, the primary amino acid structures of the cCIPs of the invention may be modified by creating amino acid substitutions or nucleic acid mutations. At least some complement regulatory activity should remain after such modifications. Similarly, nucleic acid mutations which do not change the amino acid sequences, e.g., third nucleotide changes in degenerate codons, are included within the scope of the invention. Also included are sequences comprising changes that are found as naturally occurring allelic variants of the genes for the C3/CIPs and the C5b-9/CIPs used to create the cCIPs.

Without intending to limit it in any manner, the present invention will be more fully described by the following examples.

20

Example 1

Construction of a Polynucleotide Encoding DC

The cCIP designated DC is a chimeric combination of the amino terminal leader peptide sequence of the immature CD59 polypeptide, a fragment of the DAF polypeptide containing the second, third, and fourth SCRs, a linker region comprising five Gly residues, and a peptide containing residues 1 to 103 of the mature CD59 polypeptide (Figure 1A). The leader peptide is normally removed from the nascent CD59 polypeptide after directing its transport to the exterior of the cell. Also, at least some of the carboxyl terminal amino acids of the CD59 polypeptide are removed during attachment of the GPI anchor that tethers the cCIP to the cell membrane.

DC includes, in order, amino acids -25 to +2 of SEQ ID NO:2, amino acids 62 to 251 of SEQ ID NO:1, four additional glycine residues, and amino acids 1 to 103 of SEQ ID NO:2.

The chimeric DNA construct encoding DC was prepared by first preparing a PCR-generated DNA fragment flanked with PstI sites and digested with PstI. This PstI digested PCR generated fragment (referred to hereinafter as the PstI flanked fragment) contains sequences encoding a glycine bridge as well as a fragment of DAF spanning amino acid 62 to amino acid 251 of SEQ ID NO:1. The PstI flanked fragment was ligated into the unique PstI site at the junction between the leader peptide and mature protein-encoding regions of a full length CD59 clone in plasmid pGEM7Zf (Promega Corporation, Madison, WI) containing the same CD59 encoding insert as plasmid pC8-hCD59-103, (ATCC designation 69231).

The template for the PCR reaction used to produce the PstI flanked fragment was a SalI - BamHI flanked truncated DAF cDNA clone containing sequences of DAF encoding amino acids -34 to 337 of SEQ ID NO:1, ending 10 amino acids short of the carboxyl-terminus of the full length DAF polypeptide. This SalI - BamHI flanked clone was prepared by PCR using HeLa cell (human) first strand cDNA as template. Cytoplasmic RNA was prepared from approximately 5×10^6 cells, and first strand cDNA was synthesized from $4 \mu\text{g}$ of RNA in a final volume of $100 \mu\text{l}$ using the following reaction conditions: 10mM Tris-HCl pH8.3; 50mM KCl; 1.5mM MgCl_2 ; 800ng oligo(dT)₁₅ (Promega Corporation, Madison, Wisconsin); 10mM DTT; 0.25mM dNTPs (dG, dC, dA, dT); 40U RNasin (Promega Corporation, Madison, Wisconsin); and 20U Avian Myeloblastosis Virus reverse transcriptase (Seikagaku of America, Inc. Rockville, Maryland) at 42°C for one hour.

PCR was performed following cDNA synthesis using $8 \mu\text{l}$ of first strand cDNA reaction mixture as template and the following primers: 5' primer (oligo A; SEQ ID NO:10) -- 5' CGCTGGGCGT AGCGTCGACT CGGCGGAGTC CCG 3'; and 3' primer (oligo B; SEQ ID NO:11) -- 5' GCCCATGGAT CCTAGCGTCT AAAGCAAACC TGTCAACG 3'. The PCR reaction mixture (final volume $100 \mu\text{l}$) contained the following reaction

components: 10mM Tris-HCl pH8.3; 50mM KCl; 3.5mM MgCl₂; 1.6mM dNTPs; 100ng oligo A; 100ng oligo B; and 5U AmpliTaq (Perkin-Elmer Corporation, Norwalk, Connecticut). The PCR conditions were 95°C 1 minute, 59°C 1 minute, 72°C 3 minutes for a total of 35 cycles, followed by a 10 minute extension at 72°C.

This PCR reaction produced a single DNA fragment of approximately 1200 nucleotides that was TA subcloned as an insert into plasmid pCRII according to the manufacturers directions (Invitrogen, San Diego, CA), yielding plasmid pDAF-#10. A BamHI fragment of pDAF-#10 containing the PCR generated sequences was subcloned into plasmid pcDNAI/AMP (Invitrogen, San Diego, CA) and clones were analyzed by sequencing to identify a clone with the insert in the correct orientation for expression, plasmid pDAF-c#18. The nucleotide sequence of the insert was confirmed by sequence analysis to include the sequence spanning nucleotides 78 to 1166 of SEQ ID NO:1.

PCR to produce the PstI flanked fragment was carried out using essentially the same conditions as recited above, except that the template was approximately 50 ng of BamHI linearized plasmid pDAF-c#18, the primers were oligo 54 (5' primer -- 5' GAAGAGTTCT GCAGAATCGT AGCTGCGAGG TGCC 3'; SEQ ID NO:12) and oligo 55 (3' primer -- 5' CCACGTGCTG CAGTCCTCCA CCTCCTCCTC TGCATTGAGG TGGTGGG 3'; SEQ ID NO:13), and the PCR conditions were: an initial denaturation step of 95°C 3 minutes, followed by 20 cycles of 95°C 1 minute, 55°C 1 minute, 72°C 1 minute, followed by a 10 minute extension at 72°C. The PCR product of this reaction electrophoresed as a band of approximately 500 to 600 nucleotides in length. This PCR generated fragment was TA subcloned as an insert into plasmid pCRII (Invitrogen, San Diego, CA), and sequenced to confirm that the insert contained the sequence spanning nucleotides 339 to 908 of SEQ ID NO:1. The pCRII clone was cut with PstI to yield the PstI flanked fragment, which was ligated into the unique PstI site

(spanning nucleotides 138 to 143 of SEQ ID NO:2) in the insert in the full length CD59 clone in plasmid pGEM7Zf (referred to above). The pGEM7Zf vector sequences were separated from the resulting chimeric insert with BamHI and EcoRI, and the resulting chimeric BamHI - EcoRI fragment was subcloned into BamHI - EcoRI cut pcDNAI/AMP (Invitrogen, San Diego, CA) to yield plasmid pDC#1-pcDNAI-AMP (ATCC designation 69563) referred to hereinafter as construct DC.

10

Example 2Construction of Polynucleotides Encoding CD
and Full Length DAF

15

Vectors were constructed directing the expression of full length DAF as well as of molecules with CD59 sequences located amino-terminal to DAF sequences, i.e., CD molecules. The pDAF-c#18 vector described in Example 1 was re-engineered in several steps to encode the full carboxyl-terminal region of DAF and a complete DAF amino terminal leader peptide.

20

Vectors directing the synthesis of a CD molecule were prepared comprising the carboxyl-terminal truncated form of DAF and were subsequently re-engineered in the same fashion as was pDAF-c#18 to encode the full carboxyl-terminal region of DAF.

25

The pDAF-c#18 vector was re-engineered to encode a complete DAF amino terminal leader peptide after sequence analysis revealed that the PCR reaction had generated a mutant leader sequence. The correct leader sequence was provided by a pair of complementary oligonucleotides, oligo 173 (5' TGCACGGATC CATGACCGTC GCGCGGCCGA GCGTGCCCGG 3'; SEQ ID NO:18) and oligo 174 (5' GGGCACGCTC GGCCGCGCGA CGGTCATGGA TCCG 3'; SEQ ID NO:19) that contained the correct sequence of the DAF leader. These oligos were designed to have, upon annealing to each other, restriction site overhangs complementary to the engineered SalI site introduced by oligo A, and the SacII site spanning nucleotides 78-84 of SEQ ID NO:1.

30

35

Oligo 173 and 174 were kinased, annealed, and ligated into pDAF-c#18 after digestion of the plasmid with SalI and SacII to remove the defective leader peptide region. The integrity of the leader coding region of the resulting construct, plasmid pDAF-L, was confirmed by sequence analysis.

An expression vector directing the expression of a CD molecule containing the carboxyl-terminal truncated DAF domain was constructed using a BamHI - EagI fragment obtained from the pDAF-c#18 plasmid and a CD59 cDNA BamHI - EagI fragment that was generated by PCR and restriction enzyme digestion. The PCR reaction was carried out using oligo 5 (5' primer -- 5' GGAAGAGGAT CCTGGGCGCC GCAGG 3'; SEQ ID NO:14) and oligo 53 (3' primer -- 5' GGTCTTCGGC CGCTCCACCT CCCCCACCAT TTTCAAGCTG TTCG 3'; SEQ ID NO:15) using a full length CD59 cDNA BamHI - EcoRI fragment as template.

Conditions for this reaction were essentially as described for the PCR reactions of Example 1, except that the program was an initial denaturation step of 95°C 3 minutes, followed by 10 cycles of 95°C 1 minute, 52°C 1 minute, 72°C 1 minute, followed by 10 cycles of 95°C 1 minute, 58°C 1 minute, 72°C 1 minute, followed by a 10 minute extension at 72°C. Oligo 53 contains sequences that encode glycine residues of the glycine linker and an EagI restriction site for cloning. Oligo 5 comprises a BamHI site approximately 30 base pairs upstream (5') to amino acid -25 of CD59 (SEQ ID NO:2).

The approximately 330 base pair PCR product was TA subcloned as an insert into plasmid pCRII (Invitrogen, San Diego, CA), and sequenced to confirm that the insert contained the sequence spanning nucleotides 27 to 374 of SEQ ID NO:2. This pCRII subclone was digested with BamHI and EagI. The two fragments, i.e., the DAF BamHI - EagI fragment and the CD59 BamHI - EagI fragment, were ligated in a three-way ligation into BamHI digested vector pcDNAI/Amp (Invitrogen, San Diego, CA) and restriction

mapping was undertaken to identify a clone with the correct fragment order for expression, plasmid pCD-pcDNAI-AMP.

5 Plasmid pCD-pcDNAI-AMP was tested and found not to direct detectable expression of DAF immunoreactive material on mammalian cells. This lack of expression was attributed to the carboxyl-terminal truncations present in the DAF-encoding regions in this vector. This vector and the pDAF-L vector were therefore re-engineered to
10 encode the full carboxyl-terminal region of DAF by PCR addition of a synthetic polynucleotide carboxyl-terminus as follows.

Oligo 175 (5' primer -- 5' CCCCAAATAA AGGAAGTGGAACTTCAG GTACTACCC 3'; SEQ ID NO:16) and oligo 176 (3'
15 primer -- 5' GGCTAAGTCA GCAAGCCCAT GGTACTAGC GTCCCAAGCA AACC 3'; SEQ ID NO:17) were used to add the final ten carboxyl terminal amino acids of DAF to plasmids pDAF-L and pCD-pcDNAI-AMP. Oligo 175 spans an XmnI site present in the DAF sequence, and oligo 176 contains an EcoRI
20 site.

Conditions for this reaction were essentially as described for the PCR reactions of Example 1, except that the template was approximately 13 ng of pDAF-c#18 and the program was 5 cycles of 95°C 1 minute, 50°C 1 minute,
25 72°C 1 minute with only oligo 176 present in the reaction mixture, followed by addition of oligo 175 and 20 cycles of 95°C 1 minute, 58°C 1 minute, 72°C 1 minute, followed by a 10 minute extension at 72°C.

The approximately 120 base pair PCR product was TA
30 subcloned as an insert fragment into plasmid pCRII. (Invitrogen, San Diego, CA), and sequenced to confirm that the insert contained the sequence spanning nucleotides 1184 to 1196 of SEQ ID NO:1. An EcoRI - XmnI fragment isolated from this pCRII subclone was used to
35 replace the partially homologous BamHI - XmnI fragments of plasmids pDAF-L and pCD-pcDNAI-AMP. The resulting plasmids were pFLDAF (referred to hereinafter as

construct DAF) and pCDGPI#1-pcDNAI-AMP (ATCC designation 69564; referred to hereinafter as construct CD).

Construct CD comprises sequences encoding residues -25 to +79 of SEQ ID NO:2 (CD59 -- negatively numbered residues being part of the leader peptide sequence described above), a glycine linker region including five glycine residues, two of which are amino acids 78 and 79 of SEQ ID NO:2 and three of which were engineered into the PCR primer used to generate the CD59-encoding DNA fragment, and a fragment of the DAF polypeptide including SCRs 1-4 together with the contiguous hydrophobic tail sequence of DAF (Figure 1B).

This DAF-encoding region starts at an EagI site 5 amino acids N-terminal to SCR1, i.e., it starts at amino acid -5 of SEQ ID NO:1, and ends at amino acid 347 of SEQ ID NO:1, so that it encodes the complete C-terminus of DAF. The carboxyl-terminal portion of this region includes nucleotides encoding the putative GPI anchoring signal sequence of DAF.

Example 3

Cell Surface Expression of DC and CD in Mammalian Cells

Stable transfection of constructs DAF, DC and CD was performed into the murine fibroblast cell line, Balb/3T3, by calcium phosphate transfection (Ausubel, et al., 1992). Co-transfection of the plasmid SV2Neo permitted selection on G418 (Gibco) containing media. G418 resistant colonies were then picked, expanded, and tested for the presence of cell surface expressed DC and CD by indirect immunofluorescence, using the anti-DAF monoclonal antibody BRIC 216 (Serotec, Indianapolis, IN) and the anti-CD59 monoclonal antibody MEM43 (Biodesign International, Kennebunkport, ME) and anti-murine secondary (2°) antibodies conjugated to FITC. Increased fluorescence relates to increased cell surface expression. Figure 2 illustrates cell surface expression profiles of two independent positive clones of DC (DC-A5 and DC-D6; Figures 2A and C) as well as two independent

CD clones (CD-4.15 and CD-4.21; Figures 2B and D) relative to cells transfected with SV2Neo alone as a negative control.

5 The flow cytometric profiles shown in Figure 2 illustrate that DC and CD are each expressed on the surface of the stably transfected Balb/3T3 cells and are recognized by both anti-DAF and anti-CD59 monoclonal antibodies. These results indicate that these molecules retain at least some of the conformational epitopes
10 inherent in the native parental inhibitors DAF and CD59.

Example 4

PI-PLC Analysis of DC Expressed in Mammalian Cells

A structural feature of CD59 is the anchoring of the protein to the cell surface membrane through a glycosyl-phosphatidylinositol (GPI) linkage. As discussed above,
15 DC contains the entire CD59 amino acid sequence fused with a large portion of the DAF polypeptide. To test whether this chimeric molecule is also retained on the cell surface via a GPI linkage, PI-PLC
20 (Boehringer-Mannheim, Corporation, Biomedical Products Division, Indianapolis, Indiana) digestion was performed on Balb/3T3 cells expressing DC at 1 U/ml for 1 hr at 37°C prior to FACS analysis. The result of that experiment is presented in Figure 3.

25 PI-PLC treatment removed the DC protein from the cell surface of the stably transfected Balb/3T3 cell as determined by indirect immunofluorescence using monoclonal antibodies to either CD59 (MEM43; Figure 3A) or DAF (BRIC216; Figure 3B). Mock treated cells (-
30 PI-PLC) retained cCIP DC on the cell surface, whereas PI-PLC treatment (+ PI-PLC) resulted in the loss of cell surface protein as indicated by reduced fluorescence intensity.

Example 5

DC and CD Have C3 Inhibitory Activity

35 Equivalent to That of DAF

The functional activity of DC and CD expressed in transfected Balb/3T3 cells was assessed by measuring

their ability to mimic the C3 inhibitory activity of native DAF. This analysis was carried out by incubating the transfected cells with increasing concentrations of human serum (5, 10, 20, and 40%; Figure 4A-D, respectively) and the cell surface deposition of complement component C3 was assayed by flow cytometry using an anti-C3 monoclonal antibody (anti-C3d, Quidel, San Diego, CA).

Transfected Balb/3T3 cells expressing CD59 were prepared as described in copending application Serial No. 08/205,720, entitled "Terminal Complement Inhibitor Fusion Genes and Proteins," which is referred to above, the relevant portions of which are incorporated herein by reference. Cells from each of the DAF, CD, DC, and CD59 transfectants were harvested and resuspended in 1X HBSS and 1% BSA. Approximately 1×10^5 cells/aliquot were incubated first with an anti-Balb/3T3 complement fixing polyclonal antibody at 4°C for 30 minutes. The cells were pelleted and washed twice with 1XHBSS and 1% BSA prior to the addition of human serum. The cells were incubated with increasing concentrations of human serum for 30 minutes at 37°C and were then washed once with 1XHBSS and 1% BSA before being incubated with the anti-C3 monoclonal antibody. The cells were then analyzed by flow cytometry where increasing fluorescence indicates a lack of protection from C3 deposition and therefore a lack of C3 convertase inhibition.

As seen in Figure 4, DC, CD, and DAF can equally and effectively inhibit the deposition of C3 when challenged with human serum up to 20%. For comparison, cells expressing CD59 alone (also shown in Figure 4) cannot block the deposition of C3 in that CD59 lacks C3 inhibitory activity.

Example 6Chimeric Complement Inhibitor DC and CD59 Are More Effective Inhibitors of the Lytic Activity of the Membrane Attack Complex than DAF or CD

5 As an additional test of the functional activity of the chimeric complement inhibitor proteins, stably transfected Balb/3T3 cell lines (described in Example 5) expressing DAF, CD59, CD, or DC were assayed for their ability to block the lytic activity of the membrane
10 attack complex (C5b-9).

 The lytic activity of the MAC was assessed by quantitating the efflux of the trapped cytoplasmic indicator dye, Calcein AM (Molecular Probes, Inc., Eugene, Oregon) from stably transfected Balb/3T3 cells
15 challenged with anti-Balb antibody and human serum (Figure 5).

 Transfected cells expressing DC, CD, DAF, or CD59, as well as vector alone controls, were grown to confluency in 96-well plates. Cells were washed 2X 200
20 μ l in HBSS containing 1% (w/v) BSA (HBSS/BSA).

 Calcein AM was added (10 μ M final) and the plates were incubated at 37°C for 30 minutes to allow the dye to be internalized by the cells and converted by cellular esterases into a polar fluorescent derivative that is
25 retained inside undamaged cells. The wells were then washed twice with HBSS/BSA to remove dye remaining outside the cells. The cells were then incubated with anti-Balb/3T3 IgG (2 mg/ml in HBSS/BSA), which served as an activator of the classical complement pathway. After
30 a 30 minute incubation at 23°C, unbound IgG was washed away.

 The cells were then incubated at 37°C for 30 minutes in the presence of 25% human C8 deficient serum in HBSS/BSA to allow C5b-7 to assemble on cell surfaces.
35 The cells were then incubated with purified C8 and C9 in HBSS/BSA at the concentrations indicated on the abscissa at 37°C for 30 minutes to allow the assembly of the MAC

and to thus allow complement-mediated damage to occur. (Human C8 depleted serum, as well as purified C8 and C9, were obtained from Quidel Corporation, San Diego, CA.) The medium bathing the cells was then transferred to a
5 clean 96-well plate for fluorescence measurement.

Under the conditions of this assay, the fluorescent polar derivative of Calcein AM is only released into the medium bathing the test cells if the integrity of the cell membranes is compromised. Therefore, the
10 fluorescence of the Calcein AM released into the medium bathing the test cells versus that retained in the cells provides an indirect, but accurate measure of the level of complement-mediated damage sustained by the cells. Remaining cell-associated dye was determined from a 1%
15 SDS lysate of the cells retained in the 96-well culture plates. This allowed the calculation of percent dye release using the following formulas: $\text{Total} = \text{released} + \text{retained}$, and, $\% \text{ release} = (\text{released} / \text{total}) \times 100$. Fluorescence was measured using a Millipore CYTOFLUOR
20 2350 fluorescence plate reader (490 nm excitation, 530 nm emission).

The results of the assays, as shown in Figure 5, demonstrated that DC (closed triangles) and CD59 (open circles) were equally as effective in almost completely
25 blocking the lytic activity of the MAC relative to control cells expressing neomycin resistance alone (open boxes). Complement inhibitors CD (closed circles) and DAF (closed diamonds) were also equally effective although both were less effective at blocking the MAC
30 activity than either CD59 or DC. Comparison of these results with the results of the experiments described in Example 5, which showed that equivalent protection from C3 deposition was provided by CD and DC, but not by CD59, demonstrates that DC, but not CD, provides both C3
35 convertase and MAC inhibitory activity.

Although preferred and other embodiments of the invention have been described herein, further embodiments

may be perceived and practiced by those skilled in the art without departing from the scope of the invention. The following claims are intended to cover the specific embodiments set forth herein as well as such
5 modifications, variations, and equivalents.

Throughout this application, various publications, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, and patent applications in their entireties are
10 hereby incorporated by reference into this application to more fully describe the state of the art to which the present invention pertains.

DEPOSITS

Plasmids pC8-hCD59-103, pDC#1-pcDNAI-AMP, and
15 pCDGPI#1-pcDNAI-AMP discussed above, have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20852, United States of America, in E. coli, and have been assigned the designations 69231, 69563, and 69564, respectively.
20 These deposits were made under the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purposes of Patent Procedure (1977).

The deposit referred to above having ATCC accession number 69231 was made on January 29, 1993, and those
25 having ATCC accession numbers 69563 and 69564 were made on February 9, 1994. Deposit 69231 was made in *Escherichia coli* strain DH5 α which has the following genotype: F⁻ ϕ 80dlacZ Δ M15 Δ (lacZYA-argF)U169 recA1 endA1 hsdR17(r_k⁻, m_k⁺) supE44 λ ⁻ thi-1 gyrA96 relA1. Deposits
30 69563 and 69564 were deposited in *Escherichia coli* strain TOP10F' which has the following genotype: F'⁺{lacI^q TN10(Tet^R)} mcrA Δ (mrr-hsdRMS-mcrBC) ϕ 80lacZ Δ M15 Δ lacX74 deoR recA1 araD139 Δ (ara-leu)7697 galU galK rpsL(Str^R) endA1 nupG.

References

- Adams, et al., 1991. J. Immunol. 147:3005-3011.
- 5 Albrecht, et al., 1992. Virology. 190:527-530.
- Ausubel, et al., eds., 1992. "Current Protocols in
Molecular Biology", Wiley Interscience, John Wiley
and Sons, New York.
- 10 Bordet, et al., 1900. Ann. Institut. Pasteur.
14:257.
- Bradley. 1987. in Robertson. ed. "Teratocarcinomas
and Embryonic Stem Cells a Practical Approach" IRL
Press, Eynsham, Oxford, England.
- 15 Brasile, et al., 1985. Transplantation. 40:672-675.
- Brasile, et al., 1987. Trans. Proceed. 19:894-895.
- 20 Brinster, et al., 1985. Proc. Natl. Acad. Sci. USA.
82:4438-4442.
- 25 Cosset, et al., 1990. J. Virol. 64:1070-1078.
- Chung, et al., 1985. Biochem. 256:133.
- Coyne, et al., 1992. J. Immunol. 149:2096.
- 30 Dalmasso, et al., 1992. Am. J. Pathol. 140:1157-
1166.
- Davies, et al., 1989. J. Exp. Med. 170:637-654.
- 35 Eglitis, et al., 1988. Biotechniques. 6:608-614.
- Fujita et al., 1987. J. Exp. Med. 166:1221.
- 40 Gumley, et al., 1992. J. Immunol. 149:2615-2618.
- Hogan, et al., 1986. in "Manipulating the Mouse
Embryo: A Laboratory Manual". Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
- 45 Houle et al., 1988. Blood. 71:280.
- Korman, et al., 1987, Proc. Natl. Acad. Sci. USA.
84:2150-2154.
- 50 Lovell-Badge. 1987. in Robertson. ed.
"Teratocarcinomas and Embryonic Stem Cells a
Practical Approach" IRL Press, Eynsham, Oxford,
England.
- 55

- Lublin, et al., 1988. J. Exp. Med. 168:181-194.
- Lublin, et al., 1989. Ann. Rev. Immunol. 7:35-58.
- 5 Lublin, et al., 1991. J. Exp. Med. 174:35-44.
- Luckow, et al., 1988. Bio/Technology. 6:47.
- 10 Markowitz, et al., 1988. J. Virol. 62:1120-1124.
- McMahon, et al., 1990 Cell. 62:1073-1085.
- Medof et al., J. Exp. Med. 160:1558, 1984.
- 15 Meri, et al., 1990. Immunology. 71:1-9.
- Miller, et al., 1986. Mol. Cell Biol. 6:2895-2902.
- Miller, et al., 1989. Biotechniques. 7:981-990.
- 20 Moran et al., 1992. J. Immunol. 140:1736-1743.
- Morgenstern, et al., 1990. Nucleic Acids Res. 18:3587-3596.
- 25 Norris, et al., 1993. Blood. 82:202.
- Okada, et al., 1989. J. Immunol. 143:2262-2266.
- 30 Pedersen, et al., 1990. Transgenic Techniques in Mice - A Video Guide, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- Perkins, et al., 1988. Biochemistry. 27:4004.
- 35 Petranka, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 7876-7879.
- Petranka, et al., 1993. Molec. Immunol. 30:44.
- 40 Philbrick, et al., 1990. Eur. J. Immunol. 20:87-92.
- Ripoche, et al., 1988. Biochem. J. 249:6122-6126.
- 45 Robertson, et al., 1986. Nature. 323:445-448.
- Robertson. 1987. in Robertson. ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham, Oxford, England.
- 50 Roldan, et al., 1990. EMBO J. 9:467-474.
- Rollins, et al., 1990. J. Immunol. 144:3478-3483.
- 55 Rollins, et al., 1991. J. Immunol. 146:2345-2351.

- Rother, et al., 1994. J. Virol. 68:730-737.
- 5 Sambrook, et al., 1989. Molecular Cloning: A Laboratory Manual. Second Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Sandrin, et al., 1993. Proc. Natl. Acad. Sci. USA. 90:11391.
- 10 Sawada, et al., 1989. DNA Cell. Biol. 9:213-220.
- Shevach, et al., 1989. Immunol. Today. 10:195-200.
- 15 Starzl, et al., 1993. Lancet. 341:65-71.
- Stefanova, et al., 1989. Mol. Immunol. 26:153-161.
- Su, et al., 1991. J. Cell Biol. 112:377-384.
- 20 Talib, et al., 1991. Gene. 98:289-293.
- Tone, et al., 1992. J. Mol. Biol. 227:971-976.
- 25 Venneker, et al., 1992. Exp. Clin. Immunogenet. 9:33-47.
- Walsh, et al., 1991. Eur. J. Immunol. 21:847-850.
- 30 Whitlow, et al., 1990. Cell. Immunol. 126:176-184.
- Williams, et al., 1988. Immunogenetics 27:265-272.
- Wing, et al., 1992. Immunology 76:140-145.
- 35 Wong, et al., 1985. Proc. Natl. Acad. Sci. USA. 82:7711.
- Zhao, et al., 1991. J. Biol. Chem. 266: 13418-13422.
- 40

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Fodor, William L
Rollins, Scott
Squinto, Stephen P
- (ii) TITLE OF INVENTION: Chimeric Complement
Inhibitor Proteins
- (iii) NUMBER OF SEQUENCES: 19
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Maurice M. Klee
 - (B) STREET: 1951 Burr Street
 - (C) CITY: Fairfield
 - (D) STATE: Connecticut
 - (E) COUNTRY: USA
 - (F) ZIP: 06430
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: 3.5 inch, 750 Kb storage
 - (B) COMPUTER: Dell 486/50
 - (C) OPERATING SYSTEM: DOS 6.2
 - (D) SOFTWARE: WordPerfect 6.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/205,508
 - (B) FILING DATE: 3-MAR-1994
 - (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Klee, Maurice M.
- (B) REGISTRATION NUMBER: 30,399
- (C) REFERENCE/DOCKET NUMBER: ALX-120PCT

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (203) 255-1400
- (B) TELEFAX: (203) 254-1101

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2096
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Double
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Lublin, Douglas M.
Atkinson, John P.
- (B) TITLE: Decay-Accelerating Factor:
Biochemistry, Molecular Biology, and
Function
- (C) JOURNAL: Annual Review of Immunology
- (D) VOLUME: 7
- (F) PAGES: 35-58
- (G) DATE: 1989

- 45 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTGCGACTC GGCGGAGTCC CGGCGGCGCG TCCTTGTTCT	40
AACCCGGGCGC GCC ATG ACC GTC GCG CGG CCG AGC GTG CCC	80
Met Thr Val Ala Arg Pro Ser Val Pro	
-30	
GCG GCG CTG CCC CTC CTC GGG GAG CTG CCC CGG CTG CTG CTG	122
Ala Ala Leu Pro Leu Leu Gly Glu Leu Pro Arg Leu Leu Leu	
-25 -20 -15	
CTG GTG CTG TTG TGC CTG CCG GCC GTG TGG GGT GAC TGT GGC	164
Leu Val Leu Leu Cys Leu Pro Ala Val Trp Gly Asp Cys Gly	
-10 -5 1	
CTT CCC CCA GAT GTA CCT AAT GCC CAG CCA GCT TTG GAA GGC	206
Leu Pro Pro Asp Val Pro Asn Ala Gln Pro Ala Leu Glu Gly	
5 10 15	
CGT ACA AGT TTT CCC GAG GAT ACT GTA ATA ACG TAC AAA TGT	248
Arg Thr Ser Phe Pro Glu Asp Thr Val Ile Thr Tyr Lys Cys	
20 25 30	
GAA GAA AGC TTT GTG AAA ATT CCT GGC GAG AAG GAC TCA GTG	290
Glu Glu Ser Phe Val Lys Ile Pro Gly Glu Lys Asp Ser Val	
35 40 45	
ACC TGC CTT AAG GGC ATG CAA TGG TCA GAT ATT GAA GAG TTC	332
Thr Cys Leu Lys Gly Met Gln Trp Ser Asp Ile Glu Glu Phe	
50 55	
TGC AAT CGT AGC TGC GAG GTG CCA ACA AGG CTA AAT TCT GCA	374
Cys Asn Arg Ser Cys Glu Val Pro Thr Arg Leu Asn Ser Ala	
60 65 70	
TCC CTC AAA CAG CCT TAT ATC ACT CAG AAT TAT TTT CCA GTC	416
Ser Leu Lys Gln Pro Tyr Ile Thr Gln Asn Tyr Phe Pro Val	
75 80 85	
GGT ACT GTT GTG GAA TAT GAG TGC CGT CCA GGT TAC AGA AGA	458
Gly Thr Val Val Glu Tyr Glu Cys Arg Pro Gly Tyr Arg Arg	
90 95 100	
GAA CCT TCT CTA TCA CCA AAA CTA ACT TGC CTT CAG AAT TTA	500
Glu Pro Ser Leu Ser Pro Lys Leu Thr Cys Leu Gln Asn Leu	
105 110 115	
AAA TGG TCC ACA GCA GTC GAA TTT TGT AAA AAG AAA TCA TGC	542
Lys Trp Ser Thr Ala Val Glu Phe Cys Lys Lys Lys Ser Cys	
120 125	

CCT Pro 130	AAT Asn	CCG Pro	GGA Gly	GAA Glu	ATA Ile	CGA Arg	AAT Asn	GGT Gly	CAG Gln	ATT Ile	GAT Asp	GTA Val	CCA Pro	584
GGT Gly 145	GGC Gly	ATA Ile	TTA Leu	TTT Phe	GGT Gly	GCA Ala	ACC Thr	ATC Ile	TCC Ser	TTC Phe	TCA Ser	TGT Cys	AAC Asn	626
ACA Thr	GGG Gly	TAC Tyr	AAA Lvs	TTA Leu	TTT Phe	GGC Gly	TCG Ser	ACT Thr	TCT Ser	AGT Ser	TTT Phe	TGT Cys	CTT Leu	668
ATT Ile	TCA Ser	GGC Gly	AGC Ser	TCT Ser	GTC Val	CAG Gln	TGG Trp	AGT Ser	GAC Asp	CCG Pro	TTG Leu	CCA Pro	GAG Glu	710
TGC Cys	AGA Arg	GAA Glu	ATT Ile	TAT Tyr	TGT Cys	CCA Pro	GCA Ala	CCA Pro	CCA Pro	CAA Gln	ATT Ile	GAC Asp	AAT Asn	752
GGA Gly 200	ATA Ile	ATT Ile	CAA Gln	GGG Gly	GAA Glu	CGT Arg	GAC Asp	CAT His	TAT Tyr	GGA Gly	TAT Tyr	AGA Arg	CAG Gln	794
TCT Ser 215	GTA Val	ACG Thr	TAT Tyr	GCA Ala	TGT Cys	AAT Asn	AAA Lys	GGA Gly	TTC Phe	ACC Thr	ATG Met	ATT Ile	GGA Gly	836
GAG Glu	CAC His	TCT Ser	ATT Ile	TAT Tyr	TGT Cys	ACT Thr	GTG Val	AAT Asn	AAT Asn	GAT Asp	GAA Glu	GGA Gly	GAG Glu	878
TGG Trp	AGT Ser	GGC Gly	CCA Pro	CCA Pro	CCT Pro	GAA Glu	TGC Cys	AGA Arg	GGA Gly	AAA Lys	TCT Ser	CTA Leu	ACT Thr	920
TCC Ser	AAG Lys	GTC Val	CCA Pro	CCA Pro	ACA Thr	GTT Val	CAG Gln	AAA Lys	CCT Pro	ACC Thr	ACA Thr	GTA Val	AAT Asn	962
GTT Val 270	CCA Pro	ACT Thr	ACA Thr	GAA Glu	GTC Val	TCA Ser	CCA Pro	ACT Thr	TCT Ser	CAG Gln	AAA Lys	ACC Thr	ACC Thr	1004
ACA Thr 285	AAA Lys	ACC Thr	ACC Thr	ACA Thr	CCA Pro	AAT Asn	GCT Ala	CAA Gln	GCA Ala	ACA Thr	CGG Arg	AGT Ser	ACA Thr	1046
CCT Pro	GTT Val	TCC Ser	AGG Arg	ACA Thr	ACC Thr	AAG Lys	CAT His	TTT Phe	CAT His	GAA Glu	ACA Thr	ACC Thr	CCA Pro	1088
AAT Asn	AAA Lys	GGA Gly	AGT Ser	GGA Gly	ACC Thr	ACT Thr	TCA Ser	GGT Gly	ACT Thr	ACC Thr	CGT Arg	CTT Leu	CTA Leu	1130

TCT GGG CAC ACG TGT TTC ACG TTG ACA GGT TTG CTT GGG ACG Ser Gly His Thr Cys Phe Thr Leu Thr Gly Leu Leu Gly Thr 330 335	1172
CTA GTA ACC ATG GGC TTG CTG ACT Leu Val Thr Met Gly Leu Leu Thr 340 345	1196
TAGCCAAAGA AGAGTTAAGA AGAAAATACA CACAAGTATA CAGACTGTTC	1246
CTAGTTTCTT AGACTTATCT GCATATTGGA TAAAATAAAT GCAATTGTGC	1296
TCTTCATTTA GGATGCTTTC ATTGTCTTTA AGATGTGTTA GGAATGTCAA	1346
CAGAGCAAGG AGAAAAAAGG CAGTCCTGGA ATCACATTCT TAGCACACCT	1396
GCGCCTCTTG AAAATAGAAC AACTTGCAGA ATTGAGAGTG ATTCCTTTCC	1446
TAAAAGTGTA AGAAAGCATA GAGATTTGTT CGTATTAAGA ATGGGATCAC	1496
GAGGAAAAGA GAAGGAAAGT GATTTTTTTC CACAAGATCT GAAATGATAT	1546
TTCCACTTAT AAAGGAAATA AAAAATGAAA AACATTATTT GGATATCAAA	1596
AGCAAATAAA AACCCAATTC AGTCTCTTCT AAGCAAAATT GCTAAAGAGA	1646
GATGACCACA TTATAAAGTA ATCTTTGGCT AAGGCATTTT CATCTTTCCT	1696
TCGGTTGGCA AAATATTTTA AAGGTAAAAC ATGCTGGTGA ACCAGGGTGT	1746
TGATGGTGAT AAGGGAGGAA TATAGAATGA AAGACTGAAT CTTCCCTTGT	1796
TGCACAAATA GAGTTTGGAA AAAGCCTGTG AAAGGTGTCT TCTTTGACTT	1846
AATGTCTTTA AAAGTATCCA GAGATACTAC AATATTAACA TAAGAAAAGA	1896
TTATATATTA TTTCTGAATC GAGATGTCCA TAGTCAAATT TGTAATCTT	1946
ATTCTTTTGT AATATTTATT TATATTTATT TATGACAGTG AACATTCTGA	1996
TTTTACATGT AAAACAAGAA AAGTTGAAGA AGATATGTGA AGAAAAATGT	2046
ATTTTTCCTA AATAGAAATA AATGATCCCA TTTTTTGGTA AAAAAAAAAA	2096

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1139 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Double
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: CD59 full length cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Philbrick, W.M.
Palfree, R.G.E.
Maher, S.E.
Bridgett, M.M.
Sirlin S.
Bothwell, A.L.M.
- (B) TITLE: The CD59 antigen is a structural
homologue of murine Ly-6 antigens but
lacks interferon inducibility.
- (C) JOURNAL: European Journal of Immunology
- (D) VOLUME: 20
- (F) PAGES: 87-92
- (G) DATE: JAN-1990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGCAGAAGCG GCTCGAGGCT GGAAGAGGAT CCTGGGCGCC GCAGGTTCTG 50

TGGACAATCA CA ATG GGA ATC CAA GGA GGG TCT GTC CTG TTC 92
Met Gly Ile Gln Gly Ser Val Leu Phe
-25 -20

GGG CTG CTG CTC GTC CTG GCT GTC TTC TGC CAT TCA GGT CAT 134
Gly Leu Leu Leu Val Leu Ala Val Phe Cys His Ser Gly His
-15 -10 -5

AGC CTG CAG TGC TAC AAC TGT CCT AAC CCA ACT GCT GAC TGC 176
Ser Leu Gln Cys Tyr Asn Cys Pro Asn Pro Thr Ala Asp Cys
+1 5 10

AAA ACA GCC GTC AAT TGT TCA TCT GAT TTT GAT GCG TGT CTC 218
Lys Thr Ala Val Asn Cys Ser Ser Asp Phe Asp Ala Cys Leu
15 20 25

ATT ACC AAA GCT GGG TTA CAA GTG TAT AAC AAG TGT TGG AAG 260
Ile Thr Lys Ala Gly Leu Gln Val Tyr Asn Lys Cys Trp Lys
30 35 40

TTT GAG CAT TGC AAT TTC AAC GAC GTC ACA ACC CGC TTG AGG 302
Phe Glu His Cys Asn Phe Asn Asp Val Thr Thr Arg Leu Arg
45 50 55

GAA AAT GAG CTA ACG TAC TAC TGC TGC AAG AAG GAC CTG TGT 344
Glu Asn Glu Leu Thr Tyr Tyr Cys Cys Lys Lys Asp Leu Cys
60 65

AAC TTT AAC GAA CAG CTT GAA AAT GGT GGG ACA TCC TTA TCA 386
Asn Phe Asn Glu Gln Leu Glu Asn Gly Gly Thr Ser Leu Ser
70 75 80

GAG AAA ACA GTT CTT CTG CTG GTG ACT CCA TTT CTG GCA GCA 428
Glu Lys Thr Val Leu Leu Leu Val Thr Pro Phe Leu Ala Ala
85 90 95

GCC TGG AGC CTT CAT CCC TAA G TCAACACCAG GAGAGCTTCT 470
Ala Trp Ser Leu His Pro
100

CCCAAACCTCC CCGTTCCTGC GTAGTCCGCT TTCTCTTGCT GCCACATTCT 520

AAAGGCTTGA TATTTTCCAA ATGGATCCTG TTGGGAAAGA ATAAAATTAG 570

CTTGAGCAAC CTGGCTAAGA TAGAGGGGTC TGGGAGACTT TGAAGACCAG 620

TCCTGCCCCG AGGGAAGCCC CACTTGAAGG AAGAAGTCTA AGAGTGAAGT 670

AGGTGTGACT TGAAC TAGAT TGCATGCTTC CTCCTTTGCT CTTGGGAAGA 720

CCAGCTTTGC	AGTGACAGCT	TGAGTGGGTT	CTCTGCAGCC	CTCAGATTAT	770
TTTTCCTCTG	GCTCCTTGGA	TGTAGTCAGT	TAGCATCATT	AGTACATCTT	820
TGGAGGGTGG	GGCAGGAGTA	TATGAGCATC	CTCTCTCACA	TGGAACGCTT	870
TCATAAACTT	CAGGGATCCC	GTGTTGCCAT	GGAGGCATGC	CAAATGTTCC	920
ATATGTGGGT	GTCAGTCAGG	GACAACAAGA	TCCTTAATGC	AGAGCTAGAG	970
GACTTCTGGC	AGGGAAGTGG	GGAAGTGTTT	CAGATTCCAG	ATAGCAGGGC	1020
ATGAAAACCT	AGAGAGGTAC	AAGTGGCTGA	AAATCGAGTT	TTTCCTCTGT	1070
CTTTAAATTT	TATATGGGCT	TTGTTATCTT	CCACTGGAAA	AGTGTAATAG	1120
CATACATCAA	TGGTGTGTT				1139

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1530 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Double
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: MCP (CD46) full length cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Lublin, D.M.
Liszewski, M.K.
Post, T.W.
Arce, M.A.
LeBeau, M.M.
Rebentisch, M.B.
Lemons, R.S.
Seya, T.
Atkinson, J.P.

- (B) TITLE: Molecular cloning and Chromosomal
Localization of Membrane Cofactor
Protein (MCP): Evidence for
Inclusion in the Multi-Gene Family
of Complement-Regulatory Proteins.

- (C) JOURNAL: Journal of Experimental Medicine

- (D) VOLUME: 168

- (F) PAGES: 181-194

- (G) DATE: 1988

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCTGCTTTCC	TCCGGAGAAA	TAACAGCGTC	TTCCGCGCCG	CGC	ATG	GAG	49
					Met	Glu	
					-34		
CCT	CCC	GGC	CGC	CGC	GAG	TGT	91
Pro	Pro	Gly	Arg	Arg	Glu	Cys	
	-30				-25		
CCT	GGG	TTG	CTT	CTG	GCG	GCC	133
Pro	Gly	Leu	Leu	Leu	Ala	Ala	
	-15				-10		
TTC	TCC	GAT	GCC	TGT	GAG	GAG	175
Phe	Ser	Asp	Ala	Cys	Glu	Glu	
			1			5	
GAG	CTC	ATT	GGT	AAA	CCA	AAA	217
Glu	Leu	Ile	Gly	Lys	Pro	Lys	
			15			20	
CGA	GTA	GAT	TAT	AAG	TGT	AAA	259
Arg	Val	Asp	Tyr	Lys	Cys	Lys	
25				30		35	
CCT	CTT	GCC	ACC	CAT	ACT	ATT	301
Pro	Leu	Ala	Thr	His	Thr	Ile	
	40				45		
CTA	CCT	GTC	TCA	GAT	GAC	GCC	343
Leu	Pro	Val	Ser	Asp	Asp	Ala	
	55				60		
TAT	ATA	CGG	GAT	CCT	TTA	AAT	385
Tyr	Ile	Arg	Asp	Pro	Leu	Asn	
			70			75	
GGG	ACT	TAC	GAG	TTT	GGT	TAT	427
Gly	Thr	Tyr	Glu	Phe	Gly	Tyr	
			85			90	
GAG	GGT	TAT	TAC	TTA	ATT	GGT	469
Glu	Gly	Tyr	Tyr	Leu	Ile	Gly	
95				100		105	
CTT	AAA	GGA	TCA	GTA	GCA	ATT	511
Leu	Lys	Gly	Ser	Val	Ala	Ile	
	110				115		

TGT Cys	GAA Glu	AAG Lys	GTT Val	TTG Leu	TGT Cys	ACA Thr	CCA Pro	CCT Pro	CCA Pro	AAA Lys	ATA Ile	AAA Lys	AAT Asn	553
		125					130						135	
GGA Gly	AAA Lys	CAC His	ACC Thr	TTT Phe	AGT Ser	GAA Glu	GTA Val	GAA Glu	GTA Val	TTT Phe	GAG Glu	TAT Tyr	CTT Leu	595
			140					145					150	
GAT Asp	GCA Ala	GTA Val	ACT Thr	TAT Tyr	AGT Ser	TGT Cys	GAT Asp	CCT Pro	GCA Ala	CCT Pro	GGA Gly	CCA Pro	GAT Asp	637
				155					160					
CCA Pro	TTT Phe	TCA Ser	CTT Leu	ATT Ile	GGA Gly	GAG Glu	AGC Ser	ACG Thr	ATT Ile	TAT Tyr	TGT Cys	GGT Gly	GAC Asp	679
165					170					175				
AAT Asn	TCA Ser	GTG Val	TGG Trp	AGT Ser	CGT Arg	GCT Ala	GCT Ala	CCA Pro	GAG Glu	TGT Cys	AAA Lys	GTG Val	GTC Val	721
	180					185					190			
AAA Lys	TGT Cys	CGA Arg	TTT Phe	CCA Pro	GTA Val	GTC Val	GAA Glu	AAT Asn	GGA Gly	AAA Lys	CAG Gln	ATA Ile	TCA Ser	763
		195					200					205		
GGA Gly	TTT Phe	GGA Gly	AAA Lys	AAA Lys	TTT Phe	TAC Tyr	TAC Tyr	AAA Lys	GCA Ala	ACA Thr	GTT Val	ATG Met	TTT Phe	805
			210					215					220	
GAA Glu	TGC Cys	GAT Asp	AAG Lys	GGT Gly	TTT Phe	TAC Tyr	CTC Leu	GAT Asp	GGC Gly	AGC Ser	GAC Asp	ACA Thr	ATT Ile	847
				225					230					
GTC Val	TGT Cys	GAC Asp	AGT Ser	AAC Asn	AGT Ser	ACT Thr	TGG Trp	GAT Asp	CCC Pro	CCA Pro	GTT Val	CCA Pro	AAG Lys	889
235					240					245				
TGT Cys	CTT Leu	AAA Lys	GTG Val	TCG Ser	ACT Thr	TCT Ser	TCC Ser	ACT Thr	ACA Thr	AAA Lys	TCT Ser	CCA Pro	GCG Ala	931
	250					255					260			
TCC Ser	AGT Ser	GCC Ala	TCA Ser	GGT Gly	CCT Pro	AGG Arg	CCT Pro	ACT Thr	TAC Tyr	AAG Lys	CCT Pro	CCA Pro	GTC Val	973
		265					270					275		
TCA Ser	AAT Asn	TAT Tyr	CCA Pro	GGA Gly	TAT Tyr	CCT Pro	AAA Lys	CCT Pro	GAG Glu	GAA Glu	GGA Gly	ATA Ile	CTT Leu	1015
			280				285						290	
GAC Asp	AGT Ser	TTG Leu	GAT Asp	GTT Val	TGG Trp	GTC Val	ATT Ile	GCT Ala	GTG Val	ATT Ile	GTT Val	ATT Ile	GCC Ala	1057
				295				300						
ATA Ile	GTT Val	GTT Val	GGA Gly	GTT Val	GCA Ala	GTA Val	ATT Ile	TGT Cys	GTT Val	GTC Val	CCG Pro	TAC Tyr	AGA Arg	1099
305					310					315				

TAT CTT CAA AGG AGG AAG AAG AAA GGG AAA GCA GAT GGT GGA 1141
Tyr Leu Gln Arg Arg Lys Lys Lys Gly Lys Ala Asp Gly Gly
320 325 330

GCT GAA TAT GCC ACT TAC CAG ACT AAA TCA ACC ACT CCA GCA 1183
Ala Glu Tyr Ala Thr Tyr Gln Thr Lys Ser Thr Thr Pro Ala
335 340 345

GAG CAG AGA GGC TGA AT AGATTCCACA ACCTGGTTTG CCAGTTCATC 1230
Glu Gln Arg Gly
350

TTTTGACTCT ATTAAAATCT TCAATAGTTG TTATTCTGTA GTTTCACTCT 1280

CATGAGTGCA ACTGTGGCTT AGCTAATATT GCAATGTGGC TTGAATGTAG 1330

GTAGCATCCT TTGATGCTTC TTTGAAACTT GTATGAATTT GGGTATGAAC 1380

AGATTGCCTG CTTTCCCTTA AATAACACTT AGATTTATTG GACCAGTCAG 1430

CACAGCATGC CTGGTTGTAT TAAAGCAGGG ATATGCTGTA TTTTATAAAA 1480

TTGGCAAAAT TAGAGAAATA TAGTTCACAA TGAAATTATA TTTTCTTTGT 1530

-55-

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 763 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: BABICIP full length cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Papio hamadryas

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: Baboon Spleen Lambda ZAPII cDNA
 Library, Catalog # 936103,
 Stratagene Cloning Systems,
 La Jolla, California

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

GGTTATGTGC CCACACTTGC CTAGGCTGTG AATAGTTAGT ACCTCTGATT      50
ACTTAGTTAA ATATGCTTCT AGATGAGAAG TAGCGAAAGG CTGGAAGGGA      100
TCCCGGGCGC CGCCAGGTTC TGTGGACAAT CACA ATG GGA                140
                                   Met Gly
                                   -25

ATC CAA GGA GGG TCT GTC CTG TTC GGG CTG CTG CTT GTC CTG GCT    185
Ile Gln Gly Gly Ser Val Leu Phe Gly Leu Leu Leu Val Leu Ala
          -20                      -15                      -10

GTC TTC TGC CAT TCA GGT CAT AGC CTG CAG TGC TAC AAC TGT CCT    230
Val Phe Cys His Ser Gly His Ser Leu Gln Cys Tyr Asn Cys Pro
          -5                      1                      5

```

AAC CCA ACT ACT GAC TGC AAA ACA GCC ATC AAT TGT TCA TCT GGT	275
Asn Pro Thr Thr Asp Cys Lys Thr Ala Ile Asn Cys Ser Ser Gly	
10 15 20	
TTT GAT ACG TGT CTC ATT GCC AGA GCT GGG TTA CAA GTA TAT AAC	320
Phe Asp Thr Cys Leu Ile Ala Arg Ala Gly Leu Gln Val Tyr Asn	
25 30 35	
CAG TGT TGG AAG TTT GCG AAT TGC AAT TTC AAT GAC ATT TCA ACC	365
Gln Cys Trp Lys Phe Ala Asn Cys Asn Phe Asn Asp Ile Ser Thr	
40 45 50	
CTC TTG AAG GAA AGC GAG CTA CAG TAC TTC TGC TGC AAG AAG GAC	410
Leu Leu Lys Glu Ser Glu Leu Gln Tyr Phe Cys Cys Lys Lys Asp	
55 60 65	
CTG TGT AAC TTT AAC GAA CAG CTT GAA AAT GGT GGG ACA TCC TTA	455
Leu Cys Asn Phe Asn Glu Gln Leu Glu Asn Gly Gly Thr Ser Leu	
70 75 80	
TCA GAG AAA ACA GTT GTT CTG CTG GTG ACC CTA CTT CTG GCA GCA	500
Ser Glu Lys Thr Val Val Leu Leu Val Thr Leu Leu Leu Ala Ala	
85 90 95	
GCC TGG TGC CTT CAT CCC TAAGTCAACA CCAGGAGAGC TTCTCCCATA	548
Ala Trp Cys Leu His Pro	
100	
CTCCCCGTTT CTGCGTAGTC CCCTTTCCCT CGTGCNGATT CTAAAGGCTT	598
ATATTTTCCA ACCGGATCCT GTTGGGAAAG AATAAAATTG ACTTGAGCAA	648
CCTGGCTAAG ATAGAGGGGC TCTGGAAGAC TTCGAAGACC AGTCCTGTTT	698
GCAGGGAAGC CCCACTTGAA GGAAGAAGTT TAAGAGTGAA GTAGGTGTGA	748
CTTGAGCTAG ATTGG	763

- 57 -

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 469 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: AGMCIP full length cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Cercopithecus aethiops
 (H) CELL LINE: COS-1 (ATCC CRL 1650)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	TTCTGTGGAC AATCACA ATG GGA ATC	26
	Met Gly Ile	
	-25	
CAA GGA GGG TCT GTC CTG TTC GGG CTG CTG CTT GCC CTG GCT GTC	71	
Gln Gly Gly Ser Val Leu Phe Gly Leu Leu Leu Ala Leu Ala Val		
-20 -15 -10		
TTC TGC CAT TCA GGT CAT AGC CTG CAA TGC TAC AAC TGT CCT AAC	116	
Phe Cys His Ser Gly His Ser Leu Gln Cys Tyr Asn Cys Pro Asn		
-5 1 5		
CCA ACT ACT AAC TGC AAA ACA GCC ATC AAT TGT TCA TCT GGT TTT	161	
Pro Thr Thr Asn Cys Lys Thr Ala Ile Asn Cys Ser Ser Gly Phe		
10 15 20		
GAT ACG TGT CTC ATT GCC AGA GCT GGG TTA CAA GTA TAT AAC CAG	206	
Asp Thr Cys Leu Ile Ala Arg Ala Gly Leu Gln Val Tyr Asn Gln		
25 30 35		
TGT TGG AAG TTT GCG AAT TGC AAT TTC AAT GAC ATT TCA ACC CTC	251	
Cys Trp Lys Phe Ala Asn Cys Asn Phe Asn Asp Ile Ser Thr Leu		
40 45 50		

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 396 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: SQMCIP full coding cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Saimiri sciureus
 (H) CELL LINE: DPSO 114/74 (ATCC CCL 194)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATG GGA ATC CAA GGA GGG TCT GTC CTG TTT GGG CTG CTG CTC GTC	45
Met Gly Ile Gln Gly Gly Ser Val Leu Phe Gly Leu Leu Leu Val	
-25 -20 -15	
CTG GCT GTC TTC TGC CAT TCA GGT AAT AGC CTG CAA TGC TAC AGC	90
Leu Ala Val Phe Cys His Ser Gly Asn Ser Leu Gln Cys Tyr Ser	
-10 -5 1 5	
TGT CCT CTC CCA ACC ATG GAG TCC ATG GAG TGC ACT GCG TCC ACC	135
Cys Pro Leu Pro Thr Met Glu Ser Met Glu Cys Thr Ala Ser Thr	
10 15 20	
AAC TGT ACA TCT AAT CTT GAT TCG TGT CTC ATT GCC AAA GCC GGG	180
Asn Cys Thr Ser Asn Leu Asp Ser Cys Leu Ile Ala Lys Ala Gly	
25 30 35	
TCA GGA GTA TAT TAC CGG TGT TGG AAG TTT GAC GAT TGC AGT TTC	225
Ser Gly Val Tyr Tyr Arg Cys Trp Lys Phe Asp Asp Cys Ser Phe	
40 45 50	
AAA CGC ATC TCA AAC CAA TTG TCG GAA ACT CAG TTA AAG TAT CAC	270
Lys Arg Ile Ser Asn Gln Leu Ser Glu Thr Gln Leu Lys Tyr His	
55 60 65	

[illegible]

- 61 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 387 base pairs

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Double

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

(A) DESCRIPTION: OWMCIP full coding cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Aotus trivirgatus

(H) CELL LINE: OMK (ATCC CRL 1556)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATG GGA ATT CAA GGA GGG TCT GTC CTG TTT GGG CTG CTG CTC GTC	45
Met Gly Ile Gln Gly Gly Ser Val Leu Phe Gly Leu Leu Leu Val	
-25 -20 -15	
CTG GCT GTC TTC TGC CAT TCA GGT AAT AGC CTG CAG TGC TAC AGC	90
Leu Ala Val Phe Cys His Ser Gly Asn Ser Leu Gln Cys Tyr Ser	
-10 -5 1 5	
TGT CCT TAC CCA ACC ACT CAG TGC ACT ATG ACC ACC AAC TGT ACA	135
Cys Pro Tyr Pro Thr Thr Gln Cys Thr Met Thr Thr Asn Cys Thr	
10 15 20	
TCT AAT CTT GAT TCG TGT CTC ATT GCC AAA GCC GGG TCA CGA GTA	180
Ser Asn Leu Asp Ser Cys Leu Ile Ala Lys Ala Gly Ser Arg Val	
25 30 35	
TAT TAC CGG TGT TGG AAG TTT GAG GAT TGC ACT TTC AGC CGC GTT	225
Tyr Tyr Arg Cys Trp Lys Phe Glu Asp Cys Thr Phe Ser Arg Val	
40 45 50	
TCA AAC CAA TTG TCT GAA AAT GAG TTA AAG TAT TAC TGC TGC AAG	270
Ser Asn Gln Leu Ser Glu Asn Glu Leu Lys Tyr Tyr Cys Cys Lys	
55 60 65	

-63-

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 387 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Double
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: MARCIP full coding cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Saguinus nigricollis*
 (H) CELL LINE: 1283.Lu (ATCC CRL 6297)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATG	GGA	ATC	CAA	GGA	GGG	TCT	GTC	CTG	TTT	GGG	CTG	CTG	CTC	ATC	45
Met	Gly	Ile	Gln	Gly	Gly	Ser	Val	Leu	Phe	Gly	Leu	Leu	Leu	Ile	
-25					-20					-15					
CTG	GCT	GTC	TTC	TGC	CAT	TCA	GGT	CAT	AGC	CTG	CAG	TGC	TAC	AGC	90
Leu	Ala	Val	Phe	Cys	His	Ser	Gly	His	Ser	Leu	Gln	Cys	Tyr	Ser	
-10				-5						1				5	
TGT	CCT	TAC	TCA	ACC	GCT	CGG	TGC	ACT	ACG	ACC	ACC	AAC	TGT	ACA	135
Cys	Pro	Tyr	Ser	Thr	Ala	Arg	Cys	Thr	Thr	Thr	Thr	Asn	Cys	Thr	
				10					15					20	
TCT	AAT	CTT	GAT	TCA	TGT	CTC	ATT	GCC	AAA	GCC	GGG	TTA	CGA	GTA	180
Ser	Asn	Leu	Asp	Ser	Cys	Leu	Ile	Ala	Lys	Ala	Gly	Leu	Arg	Val	
				25					30					35	
TAT	TAC	CGG	TGT	TGG	AAG	TTT	GAG	GAT	TGC	ACT	TTC	AGA	CAA	CTT	225
Tyr	Tyr	Arg	Cys	Trp	Lys	Phe	Glu	Asp	Cys	Thr	Phe	Arg	Gln	Leu	
				40					45					50	

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1039 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Double
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: cDNA to mRNA

- (A) DESCRIPTION: HVS-15 full length cDNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Herpesvirus saimiri

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: Albrecht, J.C.
Nicholas, J.
Cameron, K.R.
Newman, C.
Fleckenstein, B.
Honess, R.W.

- (B) TITLE: Herpesvirus samiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59.

- (C) JOURNAL: Virology
- (D) VOLUME: 190
- (F) PAGES: 527-530
- (G) DATE: 1992

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAGCTTCTAT TTATACTACA TTAGAGGCAT TTTTTCAAAA GCAAAAATGC	50
CTCTAATTAT ATACACTGTA CTATTTACCT CTATTACACA TTTTCTATTT	100
TAAGTCTGAT AGTGATTAAT CAAGAAAAAA GTTTGTGGTT CTCAGGGGAT	150
TAGTTCACAA GCTGTCTGAG GTTAAGGGTG TTTCTTTGGC ACTGACACAG	200
AAGTTGCTAT AAGAATTGAA GCTTGCTTTA CAAAAAGTTA CTTGTGATTA	250

- 67 -

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo A -- 5' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGCTGGGCGT AGCGTCGACT CGGCGGAGTC CCG

33

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo B -- 3' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCCCCATGGAT CCTAGCGTCT AAAGCAAACC TGTCAACG

38

-68-

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 54 -- 5' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAAGAGTTCT GCAGAATCGT AGCTGCGAGG TGCC

34

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 55 -- 3' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCACGTGCTG CAGTCCTCCA CCTCCTCCTC TGCATTCAGG TGGTGGG

47

- 69 -

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 5 -- 5' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGAAGAGGAT CCTGGGCGCC GCAGG

25

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 53 -- 3' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGTCTTCGGC CGCTCCACCT CCCCCACCAT TTTCAAGCTG TTCG

44

-70-

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 175 -- 5' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCCCAAATAA AGGAAGTGGA ACCACTTCAG GTACTACCC

39

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Oligo 176 -- 3' primer

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGCTAAGTCA GCAAGCCCAT GGTACTAGC GTCCCAAGCA AACC

44

- 71 -

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

(A) DESCRIPTION: Oligo 173

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TGCACGGATC CATGACCGTC GCGCGGCCGA GCGTGCCCGC

40

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 bases
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Other nucleic acid

(A) DESCRIPTION: Oligo 174

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGGCACGCTC GGCCGCGCGA CGGTCATGGA TCCG

34

What is claimed is:

1. A nucleic acid molecule comprising:

(a) a sequence encoding a chimeric complement inhibitor protein comprising:

(i) a first functional domain having C3 inhibitory activity; and

(ii) a second functional domain having C5b-9 inhibitory activity;

said first functional domain being amino terminal to said second functional domain; or

(b) a sequence complementary to (a); or

(c) both (a) and (b)

said molecule being substantially free of nucleic acid molecules not containing (a), (b), or (c).

2. The nucleic acid molecule of Claim 1 wherein the first functional domain comprises at least a portion of a naturally occurring C3 inhibitor protein and said chimeric complement inhibitor protein has at least about 25% of the complement inhibitory activity of said naturally occurring C3 inhibitor protein.

3. The nucleic acid molecule of Claim 1 wherein the second functional domain comprises at least a portion of a naturally occurring C5b-9 inhibitor protein and said chimeric complement inhibitor protein has at least about 25% of the complement inhibitory activity of said naturally occurring C5b-9 inhibitor protein.

4. The nucleic acid molecule of Claim 1 wherein the chimeric complement inhibitor protein includes a linker region between the first and second functional domains.

5. The nucleic acid molecule of Claim 1 wherein the chimeric complement inhibitor protein includes a transmembrane domain for cell membrane attachment.

6. The nucleic acid molecule of Claim 1 wherein the chimeric complement inhibitor protein has complement inhibitory activity against human complement.

7. A nucleic acid vector comprising the nucleic acid molecule of Claim 1 operatively linked to a second nucleic acid molecule so that a host containing the vector expresses the chimeric complement inhibitor protein.

8. A recombinant host containing the vector of Claim 7.

9. A process for protecting a non-human organ from human complement attack comprising introducing the nucleic acid molecule of Claim 6 into a pluripotent cell capable of producing a non-human transgenic animal and producing the non-human transgenic animal from said cell, whereby the resistance of an organ of said non-human transgenic animal to human complement attack is enhanced.

10. Cells isolated from the transgenic animal of Claim 9.

11. A chimeric complement inhibitor protein comprising:

(i) a first functional domain having C3 inhibitory activity; and

(ii) a second functional domain having C5b-9 inhibitory activity;

said first functional domain being amino terminal to said second functional domain.

12. The chimeric complement inhibitor protein of Claim 11 wherein the first functional domain comprises at least a portion of a naturally occurring C3 inhibitor protein and said chimeric complement inhibitor protein has at least about 25% of the complement inhibitory activity of said naturally occurring C3 inhibitor protein.

13. The chimeric complement inhibitor protein of Claim 11 wherein the second functional domain comprises at least a portion of a naturally occurring C5b-9 inhibitor protein and said chimeric complement inhibitor protein has at least about 25% of the complement

inhibitory activity of said naturally occurring C5b-9 inhibitor protein.

14. The chimeric complement inhibitor protein of Claim 11 wherein the protein includes a linker region between the first and second functional domains.

15. The chimeric complement inhibitor protein of Claim 11 wherein the protein includes a transmembrane domain for cell membrane attachment.

16. The chimeric complement inhibitor protein of Claim 11 wherein the protein has complement inhibitory activity against human complement.

1/7




FIG. 1A




FIG. 1B

2/7




FIG. 2A




FIG. 2B

3/7




FIG. 2D




FIG. 2C

4/7




FIG. 3A




FIG. 3B

RECTIFIED SHEET (RULE 91)




FIG. 4B




FIG. 4A




FIG. 4D




FIG. 4C

7/7




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02945

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/00; C07K 14/00; C07H 21/00

US CL : 435/172.3; 530/350; 536/ 23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3; 530/350; 536/ 23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

search terms: chimeric complement inhibitor protein, C3 inhibitory domain, C5b-9, transgenic animal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,873,191 (WAGNER ET AL.) 10 October 1989, see entire document.	9, 10
Y	US, A, 5,073,627 (CURTIS ET AL.) 17 December 1991, see entire document.	4, 7, 14
Y	Immunology Today, Volume 7, Numbers 7 and 8, issued 1986, Reid et al., "Complement system proteins which interact with C3b or C4b", pages 230-234, see entire reference.	1-8, 11-16
Y	Science, Volume 249, issued 13 July 1990, Weisman et al., "Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis", pages 146-151, see entire reference.	1-16

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 10 MAY 1995	Date of mailing of the international search report 01 JUN 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Suzanne Ziska</i> SUZANNE ZISKA, PH.D. Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No
PCT/US95/02945

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/02945

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Immunology, Volume 144, Number 9, issued 01 May 1990, Rollins et al., "The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9", pages 3478-3483, see entire reference.	1-16
Y	European Journal of Immunology, Volume 20, issued 1990, Philbrick et al., "The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility", pages 87-92, see entire reference.	1-16
Y	Journal of Biological Chemistry, Volume 266, Number 20, issued 15 July 1991, Zhao et al., "Amplified gene expression in CD59-transfected Chinese Hamster Ovary cells confers protection against the membrane attack complex of human complement", pages 13418-13422, see entire reference.	1-16
Y	US, A, 5,135,916 (SIMS ET AL.) 04 August 1992, see entire document.	1-16
Y	WO, A, 91/05855 (WHITE ET AL.) 02 May 1991, see entire document.	1-16

INTERNATIONAL SEARCH REPORT

International application No
PCT/US95/02945

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-10, drawn to a first product and first method of using the first product, a nucleic acid molecule and a process for protecting a non-human organ from human complement attack comprising introducing the nucleic acid into a pluripotent cell capable of producing a non-human transgenic animal.

Group II, claims 11-16, drawn to a chimeric complement protein inhibitor protein.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the protein of Group II, the chimeric complement inhibitor protein, can be made by other processes such as chemical synthesis, for example, and therefore Group II does not contain the same or corresponding technical feature of Group I. Thus, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.